From: BOIP-PATENT
Sent: Wednesday, March 3, 2021 1:26 AM
To: Tyler Eller
CC: Docketing WN; syin@boip.com.cn; John M. Guynn
Subject: [Invoice] Filing report for Malaysian National Phase Application; your Ref.: 15257.20b.8; BOIP
Ref.: BY21XM0291FGPC-MY
Attachments: BY21XM0291FGPC-MY_Preliminary Examination Report.pdf; BY21XM0291FGPC-MY_Invoice.pdf; BY21XM0291FGPC-MY_Official filing receipt.pdf; BY21XM0291FGPC-MY_Patent
Application Filed.pdf

Dear Sirs,

This is further to our email below.

Please find attached the application documents as filed, official filing receipt, Preliminary Examination Report and our Invoice for services rendered.

Malaysian Application No.: PI2021000684

Official filing date: February 22, 2021

Deadline for response to Preliminary Examination Report: <u>22 May 2021 (to file the executed Form 17); 7 November 2022</u> (to file the request for Substantive Examination)

Thank you for entrusting these filings with us. Please do not hesitate to contact us if you have any questions.

Please acknowledge receipt of this email by return.

DOCKETED

Sincerely yours,	Atty_JMGFile#_15257.20B.8		
	_{Bv} Jaclyn Boone	_{On} 03 Mar 2021	
Huijuan QIE (Ms.)	Action Instruct - Instruct - I	Response Due - Request Exam	
Lor Lorny Nup ((NI)			
	Response Due_3/3/21	- 4/22/21 - 5/22/21 - ^{11/7/22}	
	Submit IDR		
BEYOND ATTORNEYS AT LAW			
Beyond Attorneys at Law	Ve	erified	
F6, Xijin Centre, 39 Lianhuachi East Rd., Haidian District, Beijing 100036	6, China	enneu	
Tel: +86-10-8292 4510 Fax: +86-10-6337 7018	By: DPeterson	on: 03 Mar 2021	
E-mail: patent@boip.com.cn Website: www.boip.com.cn	BA: DI OLOIOOIT	<u>Un: 00 Indi 2021</u>	

This message may contain privileged and confidential information. If you are not the intended recipient, you should not disseminate, copy or take any action or place any reliance on it. If you have received this message in error, please immediately notify <u>patent@boip.com.cn</u> and delete the message and any attachment accompanying it.

Please consider the environment before printing this email.

发件人: BOIP-PATENT [mailto:patent@boip.com.cn]
发送时间: 2021年2月8日 14:54
收件人: 'Tyler Eller'
抄送: 'JGuynn'; 'Tyler Eller'; docketing@wnlaw.com; syin@boip.com.cn
主题: RE: Instructions for Malaysian National Phase Application Filing due February 7, 2021; Our Ref.:
15257.20b.8; BOIP Ref.: BY21XM0291FGPC-MY

Dear Colleagues,

This is further to our email below.

Enclosed please find the Form 17 to be signed by the applicant for the subject application. Please have it signed and the return the **original** documents to us as soon as possible.


As for the Form 22, please confirm whether the applicant acquired the rights of the invention from the inventor by virtue of assignment from the inventor's employer.

Thank you for your assistance in this matter. Should you have any question, please feel free to contact us.

Please acknowledge receipt of this email by return.

Sincerely yours,

Huijuan QIE (Ms.) For Larry Min (GM) Filing Department



Beyond Attorneys at Law Beyond Attorneys at Law F6, Xijin Centre, 39 Lianhuachi East Rd., Haidian District, Beijing 100036, China Tel: +86-10-8292 4510 | Fax: +86-10-6337 7018 E-mail: <u>patent@boip.com.cn</u> | Website: <u>www.boip.com.cn</u>

This message may contain privileged and confidential information. If you are not the intended recipient, you should not disseminate, copy or take any action or place any reliance on it. If you have received this message in error, please immediately notify <u>patent@boip.com.cn</u> and delete the message and any attachment accompanying it.

Please consider the environment before printing this email.

From: BOIP-PATENT [mailto:patent@boip.com.cn]
Sent: Monday, February 01, 2021 5:23 PM
To: 'Tyler Eller'
Cc: 'JGuynn'; 'Tyler Eller'; docketing@wnlaw.com; syin@boip.com.cn
Subject: Re: Instructions for Malaysian National Phase Application Filing due February 7, 2021; Our Ref.: 15257.20b.8; BOIP Ref.: BY21XM0291FGPC-MY

Dear Colleagues,

Thank you for entrusting us with this new Malaysian National Phase patent application.


Please note that our reference number for this case is BY21XM0291FGPC-MY. We would appreciate it if you would use it in the future correspondence.

Should you have any questions, please feel free to contact us.

Please acknowledge receipt of this email by return.

Sincerely yours,

Huijuan QIE (Ms.) For Larry Min (GM) Filing Department



Beyond Attorneys at Law Beyond Attorneys at Law F6, Xijin Centre, 39 Lianhuachi East Rd., Haidian District, Beijing 100036, China Tel: +86-10-8292 4510 | Fax: +86-10-6337 7018 E-mail: <u>patent@boip.com.cn</u> | Website: <u>www.boip.com.cn</u>

This message may contain privileged and confidential information. If you are not the intended recipient, you should not disseminate, copy or take any action or place any reliance on it. If you have received this message in error, please immediately notify <u>patent@boip.com.cn</u> and delete the message and any attachment accompanying it.

Please consider the environment before printing this email.

发件人: <u>syin@boip.com.cn</u> [<u>mailto:syin@boip.com.cn</u>] 发送时间: 2021年1月30日 8:19 收件人: 'Tyler Eller'; <u>patent@boip.com.cn</u> 抄送: JGuynn; 'Tyler Eller'; <u>docketing@wnlaw.com</u> 主题: Re: Instructions for Malaysian National Phase Application Filing due February 7, 2021; Our Ref.: 15257.20b.8

Dear John:

Thank you for your email today. Your instruction and the attachments have been received. We will take care of the case.

Best regards,

Shenmin

Shenmin Yin, Ph.D. Patent Attorney/ Trademark Attorney/ Partner

品源知识产权 BEYOND ATTORNEYS AT LAW

Beyond Attorneys at Law

New York Representative Office 9213 51st Avenue, Elmhurst, NY11373 Tel: 347-935-8012 | Fax: 212-845-9516 E-mail: syin@boip.com.cn | Website: www.boip.com.cn

From: <u>Tyler Eller</u> Date: 2021-01-29 15:44 To: <u>syin@boip.com.cn</u>; <u>patent@boip.com.cn</u> CC: <u>jquynn@wnlaw.com</u>; <u>teller@wnlaw.com</u>; <u>docketing@wnlaw.com</u> Subject: Instructions for Malaysian National Phase Application Filing due February 7, 2021; Our Ref.: 15257.20b.8 <u>VIA E-MAIL ONLY</u>

Beyond Attorneys at Law F6 Xijin Centre 39 Lianhuachi East Rd. Haidian District, Beijing 100036 China

Re: Malaysian Patent Application

Compositions and Methods for Treating Sexual Dysfunction and Enhancing Sexual Response and PleasureSerial No.:PCT/US2018/059712Filed:November 7, 2018WN Ref.:15257.20b.8Your Ref.:Please Advise

Dear Shenmin:

We represent ILYLT, LLC, a limited liability corporation organized and existing under the laws of the United States of America, which has a principal place of business at 6591 South Cottonwood Street, Murray, Utah 84107. Please see the attached 92bis and IB306 documents confirming the above listed applicant information.

Our client desires to proceed with entry into the national stage of the above-identified PCT international application. The 30 month deadline for entering the national stage is **February 7, 2021**. Please file the application on or prior to that date.

In connection with entry into the national stage with respect to the PCT application, we are sending the following documents to you by e-mail only:

- 1. a copy of the application in Word format;
- 2. a copy of the published international application;
- 3. a copy of the International Search Report & Written Opinion; and
- 4. an amended claim set for submission with the application filing.

You are authorized to proceed with the translations required for the application filing. If you require any further documentation in order to complete entry into the national stage, please notify us immediately.

Standing Instructions. In handling this matter, please take notice of and observe the following standing instructions:

- 1. Please note that no surcharges for expedited handling or translation work will be honored unless they are specifically identified to us and authorized in advance and, in any case, do not exceed 15% of the normal fee.
- 2. Please direct all correspondence concerning this matter to the attention of the undersigned.
- 3. All correspondence concerning this matter, including debit notes, should include reference to our file number, namely 15257.20b.8.
- 4. Please notify us immediately of any official communication. Please do not unduly delay its dispatch even if, for example, there is a delay in obtaining copies of the cited prior art. If you have not received instructions from us at least three (3) days prior to any *final* deadline, please contact the undersigned by telephone or facsimile for instructions. If you have not received instructions from us at least three (3) days prior to any *extendable* deadline, please apply for an extension of time and send us a reminder, which includes the new, extended deadline for responding.
- 5. Please forward one (1) copy of each prior art patent or publication cited.
- 6. In the absence of specific instruction from us, please take any action necessary to prevent abandonment during the application's pendency before the Patent Office.

Please note that responsibility for annuities other than those due at the time of filing will be handled by our annuities service, CPA.

Please immediately confirm receipt of these instructions by return e-mail.

We look forward to hearing from you. If you have any questions, please do not hesitate to contact us.

Sincerely,

Oh M. Suy

John M. Guynn

Tyler Eller Paralegal Office-Direct: 801-321-8822 EMAIL: <u>TELLER@WNLAW.COM</u>



60 East South Temple • Suite 1000 Salt Lake City, UT 84111

T: (801) 533-9800 • F: (801) 328-1707

www.wnlaw.com

PRIVACY: This e-mail may contain information that is privileged or confidential. If you are not the intended recipient, please delete the e-mail and any attachments and notify the sender immediately, and do not use, copy, or disclose to anyone any of the contents hereof.



PERBADANAN HARTA INTELEK MALAYSIA INTELLECTUAL PROPERTY CORPORATION OF MALAYSIA (Agensi dibawah KPDNHEP)



Unit 1-7 & Mezzanine, Aras 12-19 Tower B, Menara UOA Bangsar No. 5, Jalan Bangsar Utama 1 59000 KUALA LUMPUR MALAYSIA

Tel Faks(Fax) Laman Web (Web) +603 - 2299 8400 +603 - 2299 8989 www.myipo.gov.my

 APPLICATION NO
 :
 PI2021000684

 APPLICANT
 :
 ILYLT, LLC

 APPLICANT'S/AGENT'S REF.
 :
 TFL/VL/346277/21/PTN

 DATE OF MAILING
 :
 22 FEBRUARY 2021

PRELIMINARY EXAMINATION - ADVERSE FORMALITIES REPORT

Please find attached a copy of the Preliminary examination report under Section 29 of the Patents Act, relating to the following deficiencies :

ANNEX A: Deficiencies as to Regulation 5 to 11,50 and 51

□ ANNEX D: Deficiencies as to Regulation 18.

You are invited to correct the deficiencies. Corrections should be received at the above Office or Branch Offices in Sabah or Sarawak within 3 months of the above date of mailing, otherwise the application may be refused.

Date

: 22 FEBRUARY 2021

(ASMAWATI JUSOH) For Registrar of Patents <u>asmawati@myipo.gov.my</u> 03 – 22998811

То

: TAI FOONG LAM C/O GAN PARTNERSHIP D-32-02, MENARA SUEZCAP 1, KL GATEWAY 2 JALAN KERINCHI, GERBANG KERINCHI LESTARI 59200 KUALA LUMPUR MALAYSIA

(Agensi di bawah Kementerian Perdagangan Dalam Negeri Dan Hal Ehwal Pengguna)



APPLICATION NO. : PI2021000684

ADVERSE PRELIMINARY EXAMINATION REPORT [Section 29(1) of Patents Act 1983, Regulation 26(1)] [Regulations 5, 6, 7(1), 8, 9, 11 and 51)]

- □ The application does not contain all the required documents (Reg. 5) i.e. Request, Description, Claim, Abstract
- □ The application does not contain the name and address of the inventor (Reg. 6)
- □ The Request is not made on Form 1 or 14. [Reg. 7(1)]
- □ Names and addresses are not given in full in the Request (Reg. 8)
- □ The applicant's nationality/residence is not/incorrectly stated in the Request (Reg.9)
- □ The application does not designate a common representative (Reg. 11)
- ☑ The Request is not accompanied by Form 17 (Reg. 10)
- □ The Request is not accompanied by Form 22 (Reg. 10)
- □ Address for service not provided (Reg. 51)
- □ Other

Further explanations/observation:

Date : 22 FEBRUARY 2021

(ASMAWATI JUSOH) For Registrar of Patents <u>asmawati@myipo.gov.my</u> 03 – 22998811

To : TAI FOONG LAM C/O GAN PARTNERSHIP D-32-02, MENARA SUEZCAP 1, KL GATEWAY 2 JALAN KERINCHI, GERBANG KERINCHI LESTARI 59200 KUALA LUMPUR MALAYSIA



PERBADANAN HARTA INTELEK MALAYSIA INTELLECTUAL PROPERTY CORPORATION OF MALAYSIA (Agensi dibawah KPDNHEP)



Unit 1-7 & Mezzanine, Aras 12-19 Tower B, Menara UOA Bangsar No. 5, Jalan Bangsar Utama 1 59000 KUALA LUMPUR MALAYSIA

Tel Faks(Fax) Laman Web (Web) +603 - 2299 8400 +603 - 2299 8989 www.myipo.gov.my

NOTICE OF ENTERING THE NATIONAL PHASE [SECTION 780 OF PATENTS ACT 1983]

APPLICANT	: ILYLT, LLC
APPLICATION NO.	: PI2021000684
INTERNATIONAL APPLICATION NO.	: PCT/US2018/059712
REQUEST RECEIVED ON	: 08 FEBRUARY 2021
INTERNATIONAL FILING DATE	: 07 NOVEMBER 2018
AGENT'S/APPLICANT'S FILE REF.	: TFL/VL/346277/21/PTN

Please take note that upon entering the national phase, the applicant is required to comply with the requirement of the national phase in accordance with the requirements of the national phase in accordance with the Patents Act 1983.

Date

: 22 February 2021

(ASMAWATI JUSOH) For Registrar of Patents <u>asmawati@myipo.gov.my</u> 03 – 22998811

То

:

TAI FOONG LAM C/O GAN PARTNERSHIP D-32-02, MENARA SUEZCAP 1, KL GATEWAY 2 JALAN KERINCHI, GERBANG KERINCHI LESTARI 59200 KUALA LUMPUR MALAYSIA

Annex A

(Agensi di bawah Kementerian Perdagangan Dalam Negeri Dan Hal Ehwal Pengguna)



*ADVICE TO APPLICANTS - TIME PERIODS/ REQUEST FOR EXAMINATION [PCT - National Phase]

During the prosecution of an application the applicant is required to take certain actions within specified time periods. If no action is taken then the application may be refused or considered withdrawn. The attention of applicants is drawn, in particular, to the following important action required of the applicant:

(a) A request for Substantive Examination should be made by the applicant on Form 5, together with the prescribed fee, within 4 years from the international filing date of the application, failing which the application shall be deemed to be withdrawn.

OR

(b) A request for Modified Substantive Examination should be made by the applicant on Form 5A, together with the prescribed fee, within 4 years from the international filing date of the application, failing which the application shall be deemed to be withdrawn.

In accordance with regulation 27, the request for substantive examination should be accompanied by information relating to any corresponding Australian, Japan, Korean, United Kingdom, United States, European Patent Office or PCT application and its search and examination results. Note that, under Section 56(2)(e) of the Patents Act 1983, a patent may be invalidated due to failure to provide the information. Information not available at the time of requesting substantive examination may be lodged at the Registry at a later date when it becomes available.

In accordance with Section 29A(8) of the Patents Act 1983, the 4-year period cannot be extended under the provisions of Section 82. However, deferment of both examination and the provision of the information may be requested under Section 29A(6) but the request for deferment must be filed within the 4 year period.

With a view of expediting substantive examination the applicant is encouraged to lodge voluntary amendments at any time to take into account of the Malaysian legislation, to take into account of any search and examination results in order to bring the Malaysian application into substantial conformity with any Australian, Japan, Korean, United Kingdom, United States or European granted patent.

*Kindly take note that the advice provided herein is not exhaustive, and kindly refer to the Patents Act 1983 for further details.

oartnership

cates & solicitors • arbitrators • adjudicators • mediators registered potent agents * registered trade mark agents * registered industrial design agents

D-32-02, Menara SUEZCAP 1, KL Gateway 2 Jalan Kerinchi, Gerbang Kerinchi Lestari 59200 Kuala Lumpur, Malaysia

T +6 03 7931 7060 F +6 03 7931 8063 E office@ganlaw.my W www.gantaw.my

Our Ref:

8 February, 2021

TFL/VL/346277/21/PTN Your Ref: Please advise

Intellectual Property Corporation of Malaysia Patent Unit Mezzanine Level, 12 12A, 13, 15-19 Tower B, Menara UOA Bangsar 5 Jalan Bangsar Utama 1 59000 Kuala Lumpur

By Hand only

....

PARTNERS (alphabetical order) **Bahari Yeow Tien Hong** Foo Joon Liang Gan Khone Aik Kang Mei Yee Lim Zhi Jian Tai Foong Lam Tan Min Lee

SENIOR ASSOCIATES (alphabetical order) Fan Xiao Jun Foo Yuen Wah Lee Sze Ching Lee Xin Div Mah Mun Yar

ASSOCIATES (alphabetical order) Amy Um Yun Jin Carissa How Chen Huev Chew Zhen Tao Choo Wen Chun Fu Swee Theeng Lee Hul Juan Lee Hui Wen Ng Lih Jiun Sonali Nitin Nadkarni Tasha Lim Yi Chien Vincent Liew Chee Keong

Dear Sirs,

Malaysia Entry into National Phase Entry Application				
PCT Application No.	:	PCT/US2018/059712		
International Filling Date.	:	November 7, 2018		
Title	:	Compositions and Methods for Treating Sexual Dysfunction		
		and Enhancing Sexual Response and Pleasure		
Applicant	:	ILYLT, LLC		

We refer to the above matter.

Please find enclosed the following documents in support of the above application:

- (b) Two (2) copies of the Patent Form No. 2A;
- Two (2) copies of the Patent Form No. 22; (c)
- (d) Two (2) sets of Specifications comprising the:
- description; (i)
- (ii) claims; and
- (iiii) abstract;
- Two (2) copies of the signed PCT Assignment; (e)
- Two (2) copies of the published PCT Application with publication number (f) WO/2020/032988;
- Two (2) copies of the PCT International Search Report and Written Opinion of the (g) International Searching Authority; and
- for the sum of RM 470.00 as requisite filing fees for Our MBB cheque No. 166976 (h)the Form No. 2A (RM290.00) with 15 claims (RM20.00 x 5) [RM100.00], Form No. 17 (RM80.00) and Form No. 22 (RM80.00).

Please note that we will file the Patent Form No. 17 in due course once our client has transmitted to us the duly executed Patent Form No. 17.

Kindly acknowledge receipt of this letter and the enclosures by signing and returning to us the duplicate copy of this letter.

Thank you for your assistance in this matter.

Yours faithfully, **gan**partnership

Jan partnership Vincent Liew

Associate Email: <u>vincent@ganlaw.my</u> Encls.

Patents Form No. 2A PATENTS ACT 1983	For Official Use			
FEE FOR ENTERING THE NATIONAL PHASE (Regulations 25A) To : The Registrar of Patents Patents Registration Office Kuala Lumpur, Malaysia	Fee received on: Amount: *Cheque / Postal Order / Money Order / Draft / Cash No:			
Please submit this Form in duplicate together with the prescribed fee and/or reinstatement fee for international application.	Applicant's or Agent's file reference : TFL/VL/346277/21/PTN			
 I. APPLICANT(S): Name : ILYLT, LLC Address : 6591 South Cottonwood Street, Murray, Utah 84107, United States of America. 				
II. THE APPLICANT(S) REQUEST(S) ENTRY INTO THE NATIONAL PHASE IN ACCORDANCE WITH:				
*SECTION 780 🖾 *SECTION 780A 🗍 INTERNATIONAL APPLICATION NO.: PCT/US2018/059712				
III. AGENT : Applicant has appointed a patent agent in the accompanying Patents Form No. 17 Yes ⊠ No □ Agent's Registration No.: PA/2000/0102				
SIGNATURE 05/02/2021 ** (Applicant/Agent) (Date) If Agent, indicate Agent's Registration No. PA/2000/0102				
For Official Use Date application received:				

- Tick whichever is applicable
 Type name under signature and delete whichever does not apply

Patents Form No. 22	For Official Use			
PATENTS ACT 1983	APPLICATION NO.:			
	Filing Date:			
STATEMENT JUSTIFYING THE APPLICANT'S RIGHT TO A PATENT/CERTIFICATE	Request received on :			
(Regulations 10(2))	Fee Received on :			
To: The Registrar of Patents	Amount :			
Patent Registration Office	*Cheque / Postal Order / Money Order / Draft / Cash No.			
Kuala Lumpur Malaysia	Date of mailing:			
Please submit this Form in duplicate	Applicant's or Agent's file reference			
together with the prescribed fee.				
I. IN THE MATTER OF :				
Patent Application No.:	Filing Date :			
Certificate Application No.	Filing Date :			
II. TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTION AND ENHANCING SEXUAL RESPONSE AND PLEASURE				
III. APPLICANT (S)				
Name : ILYLT, LLC				
Address : 6591 South Cottonwood Street, Murray, Utah 84107, United States of America.				
IV. I/WE BELIEVE THAT THE INVENTOR(S IS AS FOLLOWS:)/INNOVATOR(S) OF THE ABOVE MENTIONED APPLICATION			
JENN, Dennis				
V. STATEMENT JUSTIFYING THE APPLICAN The applicant acquired the right assignment from the inventor's o	s of the invention from the inventor by virtue of			
VI. ADDITIONAL INFORMATION accompanies this Form : Yes V No				
VII. SIGNATURE:				
-te-p	5 February 2021			
Tai Foong L ** <i>(Applicant / Age</i>	ent)			
If Agent, indicate Agent's Registration	No. PA/2000/0102			
* Dalata whichever door not and				
 * Delete whichever does not apply. **** Type name under signature and delete whichever does not apply 				
PI 2 0 2 1 0 0 6 8 4 -				

COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTION AND ENHANCING SEXUAL RESPONSE AND PLEASURE

TECHNICAL FIELD

The invention is in the field of pharmaceutical preparations, particularly for sexual enhancement in men, women, the disabled, and the aged.

BACKGROUND ART

10

15

20

There are a variety of health issues that can impact the ability or desire to engage in intimate sexual relations, which form a healthy part of adult relationships. These include sexual dysfunction in men and women and a loss of sensitivity and pleasure. The inability to perform and/or lack of desire to engage in sexual relations can detrimentally impact a relationship and can lead to divorce, breakup, or long-term boredom. It can lead to loss of

self-esteem or even mental illness.

Men are more likely than women to have threshold desire to have sex, which is both a physical and psychological need, and are therefore more likely to initiate sex with a partner. When a man is extremely stressed, anxious or insecure, however, his ability to perform can also be inhibited physically (temporary erectile dysfunction). Older or sick men can suffer chronic erectile dysfunction ("ED"), which can be completely incapacitating relative to ability to perform. Particularly as men age and/or if suffering from chronic illness, they can experience lack of threshold desire, loss of sensitivity, loss of pleasure (collectively "arousal disorder") and/or difficulty in climaxing ("orgasmic disorder"). At the opposite end of the

p12071000684-

0 8 FEB 2021

spectrum is premature ejaculation which can severely curtail duration and satisfaction for both participants.

In women, sexual dysfunction is more complex and difficult to define but can involve lack of threshold desire, loss of sensitivity, loss of pleasure (collectively "sexual arousal disorder") and/or inability to climax ("orgasmic disorder"). Emotional and psychological sexual dysfunction may be more common among women. There are many studies that show that women commonly have insecurities about body image and carry their stresses and anxieties of life with them into the bedroom. These insecurities and stresses greatly impact the moodfactor (emotional and psychological state) and inhibit physiological arousal, such as decreased blood flow to the clitoris and labia, often making orgasm unattainable.

Compared to men, women have more complex emotions that can be barriers to threshold desire. Women are more sensitive sexually to insecurities, stresses, and anxieties than men. Books and commentators have been known to say: "sex is much more emotional for women than men." Also, men often view sex as a way to release and reduce stress and tension. In contrast, women often identify sex with increased stress and anxiety, particularly women who both work outside the home and raise children. Examples of hypothetical stresses include: "I'm not in the mood." "I'm stressed or tired from work, the kids, play dates, managing the household, dirty dishes." "Really? We're doing this now, etc.?" So, sex can becomes another item on an already stressful checklist. Examples of hypothetical anxieties include: "I think 20 I've put on a few pounds." "My butt doesn't look good." "I feel bloated and hormonal."

"How do I compare?" "Will I be able to perform for my partner, act sufficiently interested, be

interested, etc.?"

p12021000684-

2

While there are drugs (*e.g.*, Viagra®, Cialis® and Levitra®) that can remedy the physiological condition of ED and permit men to perform sexually, they generally do not restore lost sensitivity, diminished enjoyment, or difficulty in climaxing. Such drugs are generally ineffective for women because they do not adequately address issues involving lack of threshold desire, loss of sensitivity, loss of pleasure, or inability to climax (*i.e.*, because

5

20

In fact, the main reason physiological enhancers for women on the market today do not work is because they fail to address the mood-factor. Unlike men, who feel buildup of semen and equate it with sexual tension and need to find sexual release, the trigger for women to desire

they do virtually nothing to address powerful psychological forces affecting women).

- 10 sex is typically not physical but psychological and strongly correlated with mood and selfimage. Their emotional and psychological state can actually dictate physiological response, arousal and performance significantly more than in men. And while men are notorious finishers during sex, women are not so prone (50% reportedly never achieving orgasm during sex). This is generally not due to a lack of physical stimulation but rather emotional barriers
- 15 or inhibitions. Only enhancing the physiological response in women does not adequately address the inability to reach climax.

Many of the foregoing problems are particularly acute in men and women who suffer from physical ailments and/or age-related conditions that cause sexual dysfunction and/or lack of desire and enjoyment. Again, it must be emphasized that performance does not necessarily coincide with normal enjoyment of sexual relations. Drugs that only address lack of performance but fail to address diminished desire, sensitivity, and pleasure are incomplete solutions.

While there are herbal supplements that purport to address some or all of the foregoing issues, there remains a long-felt but unmet need to find compositions that effectively and reliably addresses diminished performance while also increasing desire, sensitivity and enjoyment.

5 SUMMARY OF THE INVENTION

20

The present invention relates to pharmaceutical preparations and related methods of manufacture and use for enhancing various aspects of sexual activity, and treating sexual dysfunction in men and women. To accomplish these results the pharmaceutical preparations include a combination of: (1) one or more cannabinoid compounds derived from the plant

10 genus *Cannabis*, which are included in an effective amount and/or in a ratio effective to enhance sexual pleasure (*e.g.*, threshold desire, sensitivity and/or enjoyment); and (2) one or more compounds that enhance blood flow to the genital region in order to enhance sexual response (*e.g.*, ability to perform and/or time to arousal). The combination results in increased ability to perform and enjoyment of intimate sexual activities by men and women, which treats one or more of arousal disorder, orgasmic disorder, and erectile dysfunction in both males and females.

According to several embodiments, the pharmaceutical preparations can be delivered in a manner so that the time of enhanced sexual response and sexual pleasure coincide or complement each other (*i.e.*, so that both are present at the same time at least some of the time). Methods of delivery include oral delivery, topical delivery, injection, inhalation, or combinations thereof. Advantageously, the components of the pharmaceutical preparations

can be delivered together in a single mode of delivery for simplicity and proper dosage (e.g.,

in a combined oral preparation or a topical preparation). Alternatively, the components of the pharmaceutical preparations can be pre-packaged in a kit and delivered individually, whether simultaneously or sequentially.

According to several embodiments, the one or more cannabinoid compounds derived from the plant genus *Cannabis* include at least two cannabinoid compounds that are included in amounts and/or ratios in order to address a particular condition being treated. By way of example, it has been found that persons (men or women) suffering from lack of threshold desire, sensitivity, pleasure and/or ability to climax can benefit from preparations that have a relatively higher quantity or ratio of tetrahydrocannabinol (THC) as compared to cannabidiol

10 (CBD) (*e.g.*, more than 2:1 THC/CBD). Alternatively, persons suffering from premature ejaculation (men) or who are prone to nervousness or anxiety when engaging in sexual activity (men or women) can benefit from preparations that have a relatively lower quantity THC/CBD ratio (*e.g.*, less than 0.5:1 THC/CBD). Persons with normal sexual response can benefit from an intermediate THC/CBD ratio (*e.g.*, between 0.5:1 to 2:1 THC/CBD).

- As discussed above, women can have very real insecurities about body image and carry stresses and anxieties into the bedroom. Similarly, when a man is extremely stressed, anxious or insecure, his ability to perform sexually can also be inhibited. Insecurities and stresses can greatly impact emotional and psychological state and inhibit physiological arousal, often making sex impossible for the man and/or orgasm unattainable for the woman. However, by
- addressing both the mood-factor (emotional and psychological state) and blood flow to the genitalia, physical arousal occurs easier and more naturally, which permits awareness and focus to shift to sensuality, sexual sensitivity, and sexual stimulation, enhancing sexual pleasure for both men and women, and promoting orgasms and sometimes multiple orgasms.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Disclosed herein are pharmaceutical preparations that include at least one compound that enhances sexual pleasure and at least one other compound that enhances sexual response. Also disclosed are methods of manufacturing and using such pharmaceutical preparations.

5 The term "sexual pleasure" can include a variety of physiological and/or psychological aspects or conditions that affect the amount of enjoyment of sexual activity. Examples include, but are not limited to, threshold desire to commence sexual activity, physical sensitivity during sexual activity, psychological pleasure or awareness during sexual activity, ability to reach climax, amount of pleasure leading up to climax, quality of climax, duration 10 of climax, and the like.

The term "sexual response" can include a variety of physiological and/or psychological aspects that affect the ability to perform sexual activities. In men, the most common condition is the inability to achieve or maintain an erection. In women, conditions that inhibit sexual response are more varied and complex but include, for example, inability or delay in becoming aroused while being kissed or touched in erogenous zones. In many cases such inability can be more psychological than physiological.

15

The term "sexual arousal disorder" can apply to men and women and is where a person has difficulty with arousal or arc unable to become aroused or maintain arousal during sexual activity.

6

The term "orgasmic disorder" can apply to men and women and is where a person has persistent or recurrent difficulty in achieving orgasm after sufficient sexual arousal and ongoing stimulation.

The term "low sexual desire" can apply to men and women and is where the person has lack of sexual interest and willingness to be sexual.

5

According to several embodiments, the one or more compounds that enhance sexual pleasure ("pleasure-enhancing component") include one or more cannabinoid compounds from the plant genus *Cannabis*. Examples of cannabinoid compounds include tetrahydrocannabinol ("THC"), which is a subgenus of several different isomers having different chiral centers and

is the main psychoactive constituent of *Cannabis*; cannabidiol ("CBD"), which is less or perhaps even non-psychoactive but may modulate certain effects of THC in the nervous system, cannabinol ("CBN"), tetrahydrocannabivarin ("THCV"), and cannabigerol ("CBG"). Examples of synthesized cannabinoid compounds include dronabinol (Marinol) (a pure isomer of THC, (-)-trans-Δ9-tetrahydrocannabinol, which is the main isomer found in cannabis) and nabilone (a synthetic racemic mixture consisting of the (S,S) and the (R,R) isomers of THC). Synthetic forms of THC and CBD can function the same as plant-based THC and CBD, respectively, and are therefore "cannabis extracts" unless expressly excluded.

Without being bound to any particular theory, it is postulated that pharmaceutical preparations that have higher quantities of THC have a more excitatory effect on the central

20 nervous system while pharmaceutical preparations that have lower quantities of THC and/or higher quantities of CBD can have a more calming effect. Selecting the optimal combination

of excitatory and calming effects can be advantageous in treating a particular sexual dysfunction.

In some embodiments, optimal results can be achieved when the pharmaceutical preparation includes at least two cannabinoid compounds that are included in amounts and/or ratios in order to address a particular condition being treated. It should be understood that *Cannabis* plants typically have dozens of cannabinoids and that the THC/CBD ratios expressed herein may work best when a substantial quantity (*e.g.*, most or all) of the minor cannabinoid compounds found in *Cannabis* plants are included. In fact, the THC/CBD ratios may, in at least some cases, be a proxy for the ratio of other cannabinoid compounds found in a particular *Cannabis* species. Thus, the term "consisting essentially of" does not exclude any of the minor cannabinoid compounds—any or all may be present—so long as they do not deactivate or so substantially alter the effects of TCH and/or CBD that it/they can no longer be recognized.

By way of illustration, it has been found that persons (men or women) suffering from lack of 15 threshold desire, sensitivity, pleasure and/or ability to climax (arousal disorder and/or orgasmic disorder) can benefit from preparations that have a relatively higher quantity or ratio of tetrahydrocannabinol (THC) as compared to cannabidiol (CBD). Such preparations may be euphemistically called "high excitement preparations" or "amplifying preparations". Amplifying preparations may, in some cases, include THC and no CBD.

20 Alternatively, persons suffering from premature ejaculation (men) or who are prone to nervousness or anxiety when engaging in sexual activity (men or women) can benefit from preparations that have a relatively lower quantity or ratio of THC as compared to CBD (or

higher ratio of CBD to THC). Such preparations may be euphemistically called "calming preparations" or "stabilizing preparations". Calming preparations may, in some cases, include CBD and no THC.

In yet other cases, people who do not suffer from any particular condition but nevertheless wish to enhance sexual experience can benefit from preparations that have a balanced quantity or ratio of THC as compared to CBD. Such preparations may be euphemistically called "intermediate preparations" or "balanced preparations". Such preparations will typically include both THC and CBD.

According to several embodiments, the quantity of THC in amplifying preparations can be in
a range of about 50 mg to about 500 mg per dose, or about 75 mg to about 400 mg per dose, or about 100 mg to about 300 mg per dose. To complement the THC, the quantity of CBD in amplifying preparations can be in a range of about 10 mg to about 250 mg per dose, or about 15 mg to about 200 mg per dose, or about 25 mg to about 150 mg per dose. The ratio of THC to CDB in amplifying preparations can be at least about 2:1 THC/CBD, or in a range of about 3:1 to about 20:1 THC/CBD, or about 4:1 to about 15:1 THC/CBD.

According to several embodiments, the quantity of THC in stabilizing preparations can be in a range of about 10 mg to about 250 mg per dose, or about 15 mg to about 200 mg per dose, or about 25 mg to about 150 mg per dose. To complement the THC, the quantity of CBD in stabilizing preparations can be in a range of about 50 mg to about 500 mg per dose, or about 75 mg to about 400 mg per dose, or about 100 mg to about 300 mg per dose. The ratio of THC to CDB in stabilizing preparations can be less than or equal to about 0.5:1 THC/CBD.

20

9

Stated another way, the ratio of CBD to THC can be at least about 2:1 CBD/THC, or in a range of about 0.5:1 to about 25:1 CBD/THC, or about 3:1 to about 20:1 CBD/THC, or about 4:1 to about 15:1 CBD/THC.

According to several embodiments, the quantity of THC in balanced preparations can be in a range of about 25 mg to about 400 mg per dose, or about 50 mg to about 300 mg per dose, or about 75 mg to about 250 mg per dose. To complement the THC, the quantity of CBD in balanced preparations can be in a range of 25 mg to about 400 mg per dose, or about 50 mg to about 300 mg per dose, or about 75 mg to about 250 mg per dose. The ratio of THC to CDB in balanced preparations can be in a range of about 0.1:1 to about 10:1 THC/CBD, or about 0.25:1 to about 5:1 THC/CBD, or about 0.5:1 to about 2:1 THC/CBD.

While pharmaceutical preparations can fall within the meaning of an amplifying preparation, stabilizing preparation, or balanced preparation, it will be understood that these are merely euphemistic or arbitrary categories created for the purpose of teaching general principles regarding how to manufacture a preparation designed to treat one or more particular conditions. Nevertheless, preparations may include amounts and/or ratios of cannabinoid compounds in order to have a desired balance between excitement and stabilization. In many cases the preparations may be formulated to both excite and stabilize. The relative degrees of excitement and stabilization can be selected for a specific condition or gender.

15

In view of this, compositions containing THC, alone or in combination with CBD, may include THC in a range of about 10 mg to about 500 mg per dose, or about 15 mg to about 400 mg per dose, or about 25 mg to about 300 mg per dose, or about 50 mg to about 250 mg per dose, or about 75 mg to about 150 mg per dose. The amount of THC can be at least 5 mg,

7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 50 mg, 60 mg, 75 mg, or 100 mg (lower values) and up to 750 mg, 500 mg, 450 mg, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 175 mg, 150 mg, 120 mg, or 100 mg (upper values) of THC per dose, and a ranges bounded by a lower and upper value.

Similarly, compositions containing CBD, alone or in combination with THC, may include CBD in a range of about 10 mg to about 500 mg per dose, or about 15 mg to about 400 mg per dose, or about 25 mg to about 300 mg per dose, or about 50 mg to about 250 mg per dose, or about 75 mg to about 150 mg per dose. The amount of CBD can be at least 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 50 mg, 60 mg, 75 mg, or 100 mg (lower values) and up to 750 mg, 500 mg, 450 mg, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 175 mg, 150 mg, 120 mg, or 100 mg (upper values) of CBD per dose, and a ranges bounded by a lower and upper value.

It turns out there are different strains of *Cannabis* which include differing amounts and/or ratios of the various cannabinoid compounds. For example, *Cannabis sativa* typically has a relatively high THC/CBD ratio. Conversely, *Cannabis indica* has a relative low THC/CBD ratio compared to *Cannabis sativa* (although the absolute amount of THC can be higher in *Cannabis indica* than in *Cannabis sativa*). There are also several hybrid varieties or strains of *Cannabis sativa* and *Cannabis indica* that have intermediate amounts and/or ratios of cannabinoid compounds. The amounts and/or ratios of cannabinoid compounds can change depending on the maturity of the plant, how the plant was grown, amount of artificial or natural light, climate, nutrients, and plant parts being used. In general, the buds and leaves have the highest quantities of cannabinoid compounds, while the stems and seeds have the lowest. In addition, the leaves, stems and seeds can have lower THC/CBD ratio than the buds of the same plant.

According to several embodiments, a single strain or variety of Cannabis can be used as the source of cannabinoid compounds in a given pharmaceutical preparation. By way of example, amplifying preparations can be made by extracting cannabinoid compounds from Cannabis sativa or hybrids of Cannabis sativa and Cannabis indica which are dominant toward Cannabis sativa. Conversely, stabilizing preparations can be made by extracting cannabinoid compounds from Cannabis indica or hybrids of Cannabis sativa and Cannabis indica which are more dominant toward Cannabis indica. Balanced preparations can be made by extracting cannabinoid compounds from hybrids of Cannabis sativa and Cannabis indica which are more balanced between THC and CBD (i.e., there is less dominance of one over the other as compared to hybrids used to make either amplifying or stabilizing preparations).

According to other embodiments, multiple strains or varieties of Cannabis can be used as sources of the cannabinoid compounds in a given pharmaceutical preparation. By way of example, amplifying preparations can be made by extracting cannabinoid compounds from 15 both Cannabis sativa and Cannabis indica, wherein the quantity of Cannabis sativa is substantially higher. Alternatively, amplifying preparations can be made by extracting cannabinoid compounds from Cannabis sativa and one or more hybrids of Cannabis sativa and Cannabis indica, such as those which are dominant toward Cannabis sativa. Amplifying preparations may contain plant-derived and/or synthetic THC and/or CBD.

20

5

10

Similarly, stabilizing preparations can be made by extracting cannabinoid compounds from both Cannabis sativa and Cannabis indica, wherein the quantity of Cannabis indica is higher. Alternatively, amplifying preparations can be made by extracting cannabinoid compounds from *Cannabis indica* and one or more hybrids of *Cannabis sativa* and *Cannabis indica*, such as those which are dominant toward *Cannabis indica*. In addition, leaves, stems and seeds of *Cannabis sativa* can naturally have a lower THC/CBD than buds of the same

5 plant. Amplifying preparations may contain plant-derived and/or synthetic CBD and/or THC.

Balanced preparations can be made by extracting cannabinoid compounds from both *Cannabis sativa* and *Cannabis indica*, wherein the quantities of *Cannabis indica* and *Cannabis indica* are similar. Alternatively, balanced preparations can be made by extracting cannabinoid compounds from hybrids of *Cannabis sativa* and *Cannabis indica*, such as one

10 or more that is dominant toward *Cannabis sativa* and one or more that is dominant toward *Cannabis indica*. Balanced preparations may contain plant-derived and/or synthetic CBD and/or THC.

Examples of *Cannabis sativa* dominant strains include Santa Maria, AK-47, Malawi gold, Bazooka, Durban Poison, Maui Waui, Early Bud, Early Pearl, Early Skunk Plant, Great
15 White Shark, Green Spirit, Haze, Haze Skunk, Hempstar, Jack Herer, Kali Mist, Ice, LamsBread x Skunk, Leda Uno, Malawi gold, Niagra x Shiva, Night Queen, Northern Lights x Haze, Power Plant, Purple Haze, Purple Skunk, Smokey Bear, Silver Haze, Shaman, Strawberry Cough, Sweet Island Skunk, Super Silver Haze, Swazi x Skunk, Thai, Voodoo, and White Cloud.

20 Examples of *Cannabis indica* dominant strains include Afghani#1, Amstel Gold, Bella Caio, Big Bud, Black Domina, Black African, Black Jack, Chitral, Celtic Cross, Celtic Stone, Chronic, DoubleGum, Early Girl, Early Skunk, Eclipse, Euforia, Green Spirit, G-13, Granddaddy Purple, Hawaiian Skunk, Hindu Kush, Holland's Hope, Hypno, HashPlant, Jack Flash, K2, Lemon Stinky, Mango, Master Kush, Mazar, Mighty Might, Niagra, Northern Lights, Romulan, Pink Indica, Purple High, Purple Urkel, Purple Star, Ruderalis Indica, Shiva, Sour Bubble, Southern Afghani, Super Chrystal, and Twilight.

- 5 Examples of more balanced sativa-indica hybrid strains include Blueberry kush, Rainbow Kashmiri, Blue Velvet, Blueberry, BubbleBerry, Bubblegum, Buddha Plant, Cali Orange Plant, Durban Poison x Mighty Might, Flo, First Mature, Fourway#1, Fruity Pebbles, Full Moon, Jamaican Pearl, Juicy Fruit, GrapeFruit Haze, Himalayan Gold, Island Lady, KC-33, Kerala x Skunk, Kushage, Northern Berry, NYC Diesel, Purple#1, Purple Kush, Romberry, China Shanti Shanti Shanti Shanti Shanti Shanti Shanti Basaian Shanti Haze, Suite Mise, Turtle Power, and
- 10 Shiva Shanti, Skunk Red Hair, Skunk Passion, Skunk Haze, Swiss Miss, Turtle Power, and White Widow.

The cannabinoid compounds can be extracted from one or more *Cannabis* plants using known methods, including organic solvent extraction, water extraction using hot or boiling water, mixed solvents using both an organic solvent and water, heat vaporization, fractional distillation, and the like. Depending on the method of extraction, the identifies and/or ratios of cannabinoid compounds can be altered or selected as desired. In general, extraction is able to provide a better approximation of the actual ratios of cannabinoid compounds found in a particular *Cannabis* plant as compared to combustion (*i.e.*, smoking). Combustion causes significant destruction of some of the cannabinoid compounds and can change the THC/CBD ratio.

15

20

According to several embodiments, the at least one compound that enhances sexual response ("response-enhancing component") includes one or more compounds that enhance blood flow to the genital region. Examples of response-enhancing components include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. These include known pharmaceutical drugs as well as herbal supplements that have been shown to enhance sexual response and improve performance. The response-enhancing component can address ED in men and/or physical problems in women that can inhibit or delay performance, whether from a physical or psychological standpoint.

5

10

Specific examples of response-enhancing components include sildenafil (Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®), which are pharmaceuticals, and their precursors and metabolites. Compositions within the scope of the invention may include a pharmaceutically acceptable dose of one or more of the foregoing. A pharmaceutically acceptable dose may depend on the gender, weight and/or age of the recipient and will be within known guidelines for these well-known compounds.

Herbal supplements can also increase NO levels in the blood to enhance sexual response and improve performance. They include at least 500 mg, 1 g, 1.5 g, 2 g, 2.5 g, 3 g, 4 g, 5 g, or 6 g
and up to 20 g, 15 g, 12 g, 10 g, 9 g, or 8 g, or any range between lower and upper values of: L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and/or damiana. Compositions within the scope of the invention may include a pharmaceutically acceptable dose (or dose
that is effective to raise blood NO levels) of one or more of the foregoing in order to enhance sexual response and improve performance. A pharmaceutically acceptable (or effective) dose may depend on the gender, weight and/or age of the recipient and will be within known guidelines for these compounds and compositions.

Others herbal supplemental are sold under various tradenames and include Zytenz, Vydexafil, Oxysurge, Testosyn, KOR Test Booster, Virility Ex, Natural Gain Plus, ExtenZe, Alpha T1, Happy Endings, Libido Boost Plus, Virectin, Male Extra, Climadex, Vendexafil Ultra, TestoRev, Magnum Pump XR, VigRX Plus, Ageless Male, Nugenix, Vigorplex®, Libidus,

- 5 Maxidus, Xzen XPress, Xzen Gold, Xzen Platinum, Xzen 1200, Vydexafil, AI Sports Perform, VitalKoR, Athletic Edge APE, Axcite Magnum, VirMax, Virilis Pro, Virility-X, XZone, Reload, Mojo Risen, Zoom-Zooma-Zoom, Love Rider, Ninja Mojo, Mojo Nights, EreXite, VMaxx Rx, Firminite, ZenMaxx, Black Ant, RigiRx Plus, France T253, ViaXtreme, Man Up, Herbal Vigor Quick Fix, Miraculous Evil Root, Zhen Gong Fu, GoldReallas, Liu
- Bian Li, MV5 Days, S.W.A.G., Weekend Warrior, Bali Mojo, Vimax, Tiger King, Alpha Male, Vitalikor Fast Acting, MVP Mega, MaxTreme Zen, Vicerex, Affirm XL, Kaboom Action Strips, and X-Rock. Compositions within the scope of the invention may include a pharmaceutically acceptable dose (or dose that is effective to raise blood NO levels) of one or more of the foregoing in order to enhance sexual response and improve performance. A
- 15 pharmaceutically acceptable (or effective) dose may depend on the gender, weight and/or age of the recipient and will be within known guidelines for these compounds and compositions.

The amount of the foregoing compounds or compositions can vary depending on the potency and mode of action. In general, such compounds or compositions enable men to achieve and maintain an erection by increasing blood flow to the genital region, such as by causing the body to produce nitric oxide. For reasons that may not be well-understood, they also aid

20 body to produce nitric oxide. For reasons that may not be well-understood, they also aid women when combined with one or more cannabinoid compounds as disclosed herein, which is surprising and unexpected since they typically have no effect on women when used alone. While enabling sexual activity can, by itself, increase sexual pleasure, response-enhancing components do not enhance sexual pleasure *per se* (*e.g.*, in a perfectly healthy man who does not suffer from erectile dysfunction, the use of response-enhancing drugs may not significantly affect the pleasure of the sexual act, including climax). They may simply provide the fun and novelty of longer-lasting and/or quicker threshold erections. Similarly, while cannabinoids can make a person "high" and therefore more relaxed and uninhibited,

5

they are also known to diminish sexual response and performance, particularly in men. In some cases, they can prevent achieving or maintaining an erection. In other cases, they can unnecessarily prolong or prevent climax. Unexpectedly, however, it has now been found that
combining one or more response-enhancing components with one or more pleasure-enhancing components optimizes the beneficial effects of both while offsetting or eliminating the negative effects. This greatly enhances the overall sexual experience.

Even more unexpectedly, combining one or more response-enhancing components with one or more pleasure-enhancing components can provide the elusive aphrodisiac (or "Spanish fly") that has been the subject of myth and lore but not actually achieved in reality. Unlike men, in which sexual activity is predominately (and logistically) physical and secondarily psychological, women can technically engage in sexual activity whether or not they care to or are aroused. As such, sexual pleasure is more complicated in women and is as much or more psychological as it is physical. For this reason, in both humans and animals, sexual activity is typically initiated by males rather than females. The pharmaceutical preparations disclosed herein can shift this balance and give women more initial threshold desire as well as actual sexual pleasure, which inure to the benefit of both women and their sexual partners. Without being bound to any particular theory, it is postulated that increasing blood flow to the genital region of women, while not itself having been proven to increase sexual pleasure or sexual

response, increases the effects of the cannabinoid compounds, both physically and psychologically so that, when used together, they synergistically act together to provide increased sexual pleasure and response as compared to when using either alone.

The pharmaceutical preparations can have a variety of different modes of delivery, which can be gender-specific or otherwise tailored for the specific needs or desires of the patient. 5 According to an embodiment, the pharmaceutical preparation can be designed as a topical (external or internal, including body cavity, but excluding oral and nasal), e.g., massage oils, lotions, gels, creams, lubricants, genital sprays, vaginal patch, vaginal suppository, or anal suppository. Alternatively or in addition, they can be formulated for ingestion, e.g., capsules, tablets, oral drops, lozenges, lollipops, and food preparations, *i.e.*, "edibles" (aka ingestible, 10

in contrast to sublingual or buccal absorption), such as brownies, cookies, chocolates, chews, gum drops, soft candies, hard candies, liquid shots, and the like). Alternatively, they can be formulated for inhalation into the lungs (e.g., by a heat vaporizer ("vape") or nebulizer).

Capsules include any delivery form that includes an outer covering enclosing the actives. The outer covering can be any suitable material known in the art, such as gelatin, starch, cellulose 15 ether, gum, protein, or polysaccharide. Tablets include actives compressed into a solid form, sometimes with a binder or inert component. While many capsules and tablets are configured to be swallowed whole, they may also be divided into pieces and swallowed, in some cases chewed and swallowed, sometimes crushed by the teeth to release a liquid, gel or solid that is swallowed. Some tablets or capsules can be used vaginally or anally as suppositories. Or they 20 may be used buccally or sublingually.

A "solid ingestible" includes dosage forms that can be swallowed with no or minimal chewing (*e.g.*, some types of capsules and tablets); dosage forms that are chewed and swallowed, such as food preparations and other edibles (*e.g.*, brownies, cookies, desserts, chocolates, chews, gum drops, soft candies, and some types of capsules and tablets); dosage forms that dissolve in the mouth and arc swallowed (*e.g.*, hard candies, lollipops, lozenges, some types of capsules and tablets). A characteristic of a solid ingestible is that the active is intended to be absorbed in the stomach, gut and/or small intestine, as opposed to being primarily absorbed buccally or sublingually.

A "liquid ingestible" includes a liquid or gel that can be swallowed with little or no chewing.
A characteristic of a solid ingestible is that the active is intended to be absorbed in the stomach, gut and/or small intestine, as opposed to being primarily absorbed buccally or sublingually. A liquid ingestible can be a shot, a drink, gel pack, oral drops, and the like.

"Dual delivery" compositions can be applied and absorbed in more than one way. Examples include flavored body oils, creams, lotions, liquids, gels, and lubricants, which can be placed on areas of the body where they can be readily absorbed, such as on the skin, especially on or in the genital region, anal region, or armpits of a man or woman, and optionally licked or ingested by the other partner during application and sex play. In some cases, a composition can be placed on or in the genital (or anal) region of one partner and transferred to the genital (or anal) region of the other partner during sex play and intercourse. Such compositions can be placed on or in sex toys, vibrators, dildos, condoms, other prophylactic devices, props, and

the like.

5

In general, extraction of cannabinoids and then delivery without combustion provides superior results compared to smoking weed and ingesting an ED drug. Combustion destroys a significant quantity of cannabinoid compounds and can change their ratios, which makes proper dosing difficult. Smoking weed and ingesting an ED drug also suffers from the inability to control the timing of each, since smoking causes almost instantaneous high while ingesting an ED drug takes time for the body to metabolize. The result can be premature cannabinoid effect, with delayed blood-flow increasing effect coupled with reduced cannabinoid effect when it is desirable for both to be maximized. Delivering both the pleasure-enhancing and performance-enhancing components in a single preparation and/or in the same manner can better control dosing and timing.

5

10

20

Where it is desired to inhale a cannabinoid infused material, such as a liquid, gel or paste, vaporizing apparatus known in the art for delivering nicotine can be used. The concentration of cannabinoids in the vape juice or oil can be adjusted, similar to how it is done when delivering nicotine using a vape stick, hookah, or mod box, so that a predetermined number

15 of puffs will deliver a predetermined amount of the one or more cannabinoids of interest.

Nebulizers known in the art used in hospitals, for hospice or for home care can be used to deliver a predetermined amount of cannabinoids.

In addition to the cannabinoids, the other active for increasing blood flow can be delivered by any suitable means to provide a predetermined quantity of the active. These include oral ingestion, topical delivery, and inhalation, although oral ingestion by capsule or table is currently the most prescribed delivery method.

EXAMPLES

For purposes of the following examples, sexual pleasure and sexual response are assigned a value on a scale of 1 to 10, with 1 being the lowest and 10 being the highest. Three categories in men were measured: hardness of erection on a scale of 1 to 10; sensitivity on a scale of 1 to 10; and strength of orgasm on a scale of 1 to 10. Three categories in women are measured:

5 10; and strength of orgasm on a scale of 1 to 10. Three categories in women are measured: threshold desire on a scale of 1 to 10; sensitivity on a scale of 1 to 10; and strength of orgasm on a scale of 1 to 10.

EXAMPLE 1A

20

The subject was a 41 year old male. The marijuana strain used to provide the cannabinoid compounds was AK-47 hybrid strain. The cannabinoid compounds from marijuana were delivered orally usable an edible. Marijuana plant parts (mostly leaves and buds) were ground up and simmered in vegetable oil for 3 hours to extract cannabinoid compounds (primarily THC and CBD) and then strained. The cannabinoid infused oil was assumed to contain roughly the same ratio of THC to CBD in the plant parts (as well as other cannabinoids in the plant parts). The minor cannabinoids did not negate or substantially alter the predominating effects of the THC and CBD.

The infused oil was used in place of the oil called for in normal preparation of brownies per instructions. The cannabinoid infused oil was blended in an amount of 1/4 ounce per 18 ounce fudge brownie mix. Brownies containing the extracted cannabinoid compounds were prepared from the mixed batter by placing into a small cake pan (6 in²) and baked in the over according to instructions. A small pan of brownies was cut up into 3 inch squares.

The subject ingested two brownies and one XZEN pill. [Note: it was later discovered that XZEN used in this and other examples herein may have been tainted with a pharmaceutical, such as sildenafil, tadalafil, or vardenafil, or biosimilar compound, because it was pulled from the market and modified.] The subject started noticing the effects of both after about 1 hour and commenced sexual activity with a female partner shortly thereafter. The subject was able to obtain and maintain a hard erection and sensitivity and pleasure during sex were increased. The subject was able to last longer than usual and, in this case, sex lasted about 30 minutes. At the culmination, ejaculation was very intense. The statistics were (on a scale of 1 to 10): hardness of erection: 9; sensitivity: 8; strength of orgasm: 10.

10 EXAMPLE IB

5

15

The female partner in Example 1A weighed less than the male subject in Example 1A and ingested one cannabinoid infused brownie square and also experienced heightened sensitivity (8) and pleasure during the sexual activity, which was attributed to reduced anxiety and inhibition and increased threshold desire. The female did not ingest any blood flow enhancements. It is postulated that the female partner would further benefit from combining ingestion of the cannabinoid edible with a component that increases blood flow to the female genital region in order to increase threshold desire (*e.g.*, 8 as a result of swelling and thickening of the clitoris and labia), as well as more intense orgasm (*e.g.*, 8) as a result of the combined psychological and physiological effects of ingesting both the pleasure-enhancing

20 and performance-enhancing component.

EXAMPLE 1C

The female partner ingests the cannabinoid edible with a component that increases blood flow to the female genital region. The combination increases threshold desire (*e.g.*, 8 as a result of swelling and thickening of the clitoris and labia), as well as more intense orgasm

5 (e.g., 8) as a result of the combined psychological and physiological effects of ingesting both the pleasure-enhancing and performance-enhancing component.

EXAMPLE 2A

The subject was a 70 year old male. The marijuana strain used to provide the cannabinoid compounds was AK-47. The cannabinoid compounds were extracted by simmering 1/4 ounce

10 of marijuana in 1 cup avocado oil to make butter. The subject spread approximately 1 tablespoon of the butter onto toast and then ingested the toast and one XZEN pill on an empty stomach. After 45 minutes the subject felt some flushing and effects of the cannabinoid compounds.

After one hour the subject had a hard crection and proceeded to have sex with a female
partner of similar age. The sex lasted an amazing 2 hours and the subject was able to
ejaculate 5 times within that time span, which would be remarkable for a young man, but in
this case the subject was a 70 year old man. The statistics were (on a scale of 1 to 10):
hardness of erection: 10; sensitivity: 9; strength of orgasm: 9. This example exemplifies the
benefit to an older man of using cannabinoids with a higher ratio of THC:CBD (at least 2:1).
The subject's opinion was that the sex was like being a young man all over again ("21

again"), and his overall mood in general improved dramatically (demeanor and disposition), which was another unexpected benefit.

The female partner in Example 2A did not ingest any enhancements. However, it is postulated that the female partner would benefit from ingesting the preparations disclosed herein and experience increased threshold desire (8), heightened sensitivity and pleasure (8),

5

10

and more powerful orgasm (8).

EXAMPLE 2B

This example is repeated but with the man ingesting Viagra® instead of XZEN with similar results. The example is modified by substituting Viagra® or XZEN with any other known male enhancement, such as Cialis®, Levitra®, L-arginine, horny goat weed, and the like.

EXAMPLE 3A

The subject was a 41 year old male. The marijuana strain used to provide the cannabinoid compounds was Blueberry Kush. The cannabinoid compounds were delivered orally using an edible. The marijuana plant parts (mostly leaves and buds) were ground up and simmered in vegetable oil for 3 hours to extract cannabinoid compounds and then strained. The cannabinoid infused oil was assumed to contain roughly the same ratio of THC to CBD in the plant parts (as well as other cannabinoids in the plant parts). The minor cannabinoids did not negate or substantially alter the predominating effects of the THC and CBD.

The infused oil was used in place of the oil called for in normal preparation of brownies per instructions. The cannabinoid infused oil was blended in an amount of 1/4 ounce per 18 ounce fudge brownie mix. Brownies containing the extracted cannabinoid compounds were prepared from the mixed batter by placing into a small cake pan (6 in²) and baked in the over

5 according to instructions. A small pan of brownies was cut up into 3 inch squares.

The subject ingested two brownies and one XZen pill. The subject started noticing the effects of both after about 1 hour and commenced sexual activity shortly thereafter. The subject was able to maintain a hard erection and sensitivity was increased. The subject was able to last longer and sex lasted about 45 minutes with a female partner. Ejaculation was very intense. The subject was thereafter able to achieve another erection after 30 minutes and commenced

- The subject was thereafter able to achieve another erection after 30 minutes and commenced sexual activity again, which lasted about 30 minutes, and able to achieve a second orgasm. The statistics were (on a scale of 1 to 10): hardness of erection: 9; sensitivity: 8; strength of orgasm: 9. This example, as compared to Examples 1 and 2, demonstrates the beneficial effects for a relatively young, healthy man when using a cannabinoid having a more balanced
- 15 ratio of THC to CBD (which was closer to 1:1 than in Example 1 and possibly less 1:1), relative to the ability to last longer.

EXAMPLE 3B

20

The female partner in Example 3A ingested one cannabinoid infused brownie square and also experienced heightened sensitivity and pleasure (8) during the sexual activity, which was attributed to reduced anxiety and inhibition and increased threshold desire. The female did not ingest any blood flow enhancements. It is postulated that the female partner would further benefit from combining ingestion of the cannabinoid edible with a component that increases blood flow to the female genital region in order to increase threshold desire (*e.g.*, 8 as a result of swelling and thickening of the clitoris and labia), as well as more intense orgasm (8) as a result of the combined psychological and physiological effects of ingesting both the pleasureenhancing and performance-enhancing component.

5 EXAMPLE 4A

15

The subject was a 70 year old male. The marijuana strain used to provide the cannabinoid compounds was Blueberry Kush. The cannabinoid compounds were extracted by simmering 1/4 ounce of marijuana in 1 cup avocado oil to make butter. The subject spread approximately 1 tablespoon of the butter onto toast and then ingested the toast and one XZEN pill on an empty stomach. After 45 minutes the subject felt some flushing and effects of the

pill on an empty stomach. After 45 minutes the subject felt some flushing and effects of the cannabinoid compounds.

After one hour the subject had a hard erection and proceeded to have sex with a female partner of similar age. The sex lasted 2 hours and the subject was able to ejaculate 3 times within that time span. The statistics were (on a scale of 1 to 10): hardness of erection: 10; sensitivity: 9; strength of orgasm: 9. This example demonstrated that while a clear benefit was obtained by the subject ingesting a balanced ratio of THC:CBD, the results were not quite as dramatic as Example 2, in which the subject ingested a higher ratio of THC:CBD and was able to achieve 5 orgasms instead of 3.

The female partner did not ingest any enhancements. However, it is postulated that the female partner would benefit from ingesting the preparations disclosed herein and experience increased threshold desire (8), heightened sensitivity and pleasure (8), and more powerful orgasm (8).

EXAMPLE 5

A 50 year old male ingested a single brownie prepared according to Example 3 and one XZcn
pill. The subject felt the effects of both components and was able to achieve an erection more quickly and maintain it longer. The subject engaged in sexual activities with a female partner within about 1-2 hours of ingestion lasting about 30 minutes. The subject had an erection of about an 8, heightened sensitivity of about 8; and a more intense orgasm of about 8. It is postulated that the male subject might have benefitted more using the higher THC:CBD
preparation and/or ingesting an increased quantity of the edible.

The female partner did not ingest any enhancements. However, it is postulated that the female partner would benefit from ingesting the preparations disclosed hercin and experience increased threshold desire (8), heightened sensitivity and pleasure (8), and more powerful orgasm (8).

15 EXAMPLE 6

20

The subject is a 22 year old male who is provided with an infused edible made according to any of the foregoing Examples. The subject is strong and virile but prone to premature cjaculation. The subject ingests the infused edible together with a component that increases blood flow to the genital region (*e.g.*, XZen or part of a Viagra®). After 20-30 minutes the subject has a hard erection and proceeds to have sex with a partner. When using an edible

with high THC:CBD ratio, the sex is brief (about 1-3 minutes) but intense. The statistics are (on a scale of 1 to 10): hardness of erection: 10; sensitivity: 8; strength of orgasm: 8.

Alternatively, the subject ingests a cannabinoid infused edible having a higher ratio of CBD:THC and experiences the same quality of erection, sensitivity, and strength of orgasm

5 but is able to last much longer than usual (e.g., 15-45 minutes), which greatly boosts the subject's confidence when engaging in sexual activities with others. Due to the subject's age, he is able to achieve multiple orgasms with fast or immediate recovery between ejaculations.

This example demonstrates that, while a clear benefit is obtained by the subject ingesting a high ratio of THC:CBD, the results are objectively much better when the subject ingests a much lower ratio of THC:CBD (or higher ratio of CBD:THC). It is postulated that a more balanced ratio of THC:CBD would provide an intermediate benefit between the extremes described herein.

EXAMPLE 7

10

The subject is a 21 year old female who is provided with an infused edible made according to any of the foregoing Examples. The subject is healthy but inexperienced and nervous when engaging in sexual activity, which decreases threshold desire, pleasure and fulfillment, and makes it difficult or impossible for the subject to achieve orgasm. The subject ingests the infused edible together with a component that increases blood flow to the genital region (*e.g.*, XZen for Women or part of a Viagra®). After about 1 hour the subject feels flushing and the effects of the cannabinoid compounds and the blood flow enhancer, including increased swelling of the vulva and nipples which, although largely physiological, combine with the enhanced psychological effects of excitement and decreased anxiety provided by the infused edible to increase threshold desire (*e.g.*, 9).

When the subject ingests an edible containing a high THC:CBD ratio, the subject may be more physically aggressive but might still have difficulty achieving orgasm regularly. It is postulated that a higher CBD:THC ratio would provide a calming effect that permits deeper psychological appreciation and enjoyment of sexual activity, leading to more reliable and fulfilling orgasms. Depending on the woman, an intermediate TCD:CBD ratio may be sufficiently calming, yet more excitatory so as to promote quicker and/or multiple orgasms.

EXAMPLE 8

5

20

A 25 year old female subject is provided with an infused edible made according to any of the foregoing Examples. The subject ingests the infused edible together with a component that increases blood flow to the genital region (*e.g.*, XZen for Women or part of a Viagra®). After about 1 hour the subject feels flushing and the effects of the cannabinoid compounds, including increased swelling of the vulva and nipples which, although largely physiological, combine with the enhanced psychological effects of excitement and decreased anxiety provided by the infused edible to increase threshold desire.

After one hour the subject commences sexual activity with a 41 year old male partner. The subject experiences heightened sensitivity (9) and pleasure and is able to climax more quickly and more powerfully (9) than usual. Depending on the endurance of her male sex partner, the female subject is able to achieve multiple orgasms as a result of the increased physiological and psychological awareness and sensitivities provided by the combined use of pleasure-

enhancing and performance-enhancing components. Because of the female subject's age (25) and sexual confidence, it is postulated that the subject would, like the 41 year old subject of Examples 1 and 3, benefit from an edible having a balanced THC:CBD ratio.

EXAMPLE 9

A 68 year old female subject of normal sexual experience and activity for her age is provided 5 with an infused edible made according to any of the foregoing Examples. The subject ingests the infused edible together with a component that increases blood flow to the genital region (e.g., XZen for Women or part of a Viagra®). After about 1 hour the subject feels flushing and the effects of the cannabinoid compounds and blood flow enhancer, including increased swelling of the vulva and nipples which, although largely physiological, combine with the 10 enhanced psychological effects of excitement and decreased anxiety provided by the infused

edible to increase threshold desire.

After one hour the subject commences sexual activity with a male partner of similar age. The subject experiences high threshold desire (7), heightened sensitivity (9) and is able to climax more quickly and more powerfully (9) than usual. Depending on the endurance of her male 15 sex partner, the female subject is able to achieve multiple orgasms as a result of the increased physiological and psychological awareness and sensitivities provided by the combined use of pleasure-enhancing and performance-enhancing components. Because of the female subject's age (68), it is postulated that the subject would, like the 70 year old subject of Examples 2 and 4, benefit more from an edible having a higher THC:CBD ratio.

20

EXAMPLE 10

5

A 45 year old female subject is provided with an infused edible made according to any of the foregoing Examples. The subject ingests the infused edible together with a component that increases blood flow to the genital region (*e.g.*, XZen for Women or part of a Viagra®). After about 1 hour the subject feels flushing and the effects of the cannabinoid compounds and blood flow enhancer, including increased swelling of the vulva and nipples which, although largely physiological, combine with the enhanced psychological effects of excitement and decreased anxiety provided by the infused edible to increase threshold desire (9).

After one hour the subject commences sexual activity with a male partner of similar age. The subject experiences heightened sensitivity (9) and pleasure and is able to climax more quickly and more powerfully (9) than usual. Depending on the endurance of her male sex partner, the female subject is able to achieve multiple orgasms as a result of the increased physiological and psychological awareness and sensitivities provided by the combined use of pleasure-enhancing and performance-enhancing components. Because of the female subject's age (45), it is postulated that the subject would, like the 50 year old subject of Example 5, benefit more from an edible having a higher THC:CBD ratio and/or ingesting a higher quantity of edible having a balanced THC:CBD ratio.

EXAMPLE 11

A 70 year old female subject who rarely engages in sexual activity because of lost desire and pleasure is provided with an infused edible made according to any of the foregoing Examples. The subject ingests the infused edible together with a component that increases

31

blood flow to the genital region (*e.g.*, XZen for Women or part of a Viagra®). After about 1 hour the subject feels flushing and the effects of the cannabinoid compounds and blood flow enhancer, including increased swelling of the vulva and nipples which, although largely physiological, combine with the enhanced psychological effects of excitement and decreased enviets provided by the infused edible to increase threshold desire (7 or 8).

5 anxiety provided by the infused edible to increase threshold desire (7 or 8).

After one hour the subject commences sexual activity with a male partner of similar age. The subject experiences heightened sensitivity (7 or 8) and pleasure and is able to achieve climax (6 or 7), perhaps for the first time in a long time or ever. Depending on the endurance of her male sex partner, the female subject is able to achieve multiple orgasms as a result of the increased physiological and psychological awareness and sensitivities provided by the combined use of pleasure-enhancing and performance-enhancing components. Because of the female subject's age (70), it is postulated that the subject might, like the 70 year old subject

of Examples 2 and 4, benefit more from an edible having a higher THC:CBD ratio.

EXAMPLE 12

10

- 15 Any of the foregoing examples is modified by providing at least one of the components (*e.g.*, pleasure-enhancing component) in a preparation that can delivered by inhalation. Examples include, for example, vaporizers that heat one or more components of the pharmaceutical preparation with water or "vape juice" (*e.g.*, glycerin and/or propylene glycol) to provide a vapor that carries the components of interest and can be inhaled. The temperature and/or
- 20 selection of vaporizing liquids can affect the concentration and/or ratio of cannabinoids delivered to the user.

EXAMPLE 13

Any of the foregoing examples is modified by providing at least one of the components (e.g., pleasure-enhancing component) in a topical preparation that can be applied to any region of the body able to rapidly absorb the active components. Examples include, for example, the genital and/or anal regions of men and women.

The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which

come within the meaning and range of equivalency of the claims are to be embraced within 10 their scope.

⁵

CLAIMS

1. A pharmaceutical composition for treating sexual dysfunction in a human, comprising one or more dosage forms configured to deliver:

a cannabinoid component comprised of at least one of 5 mg to 500 mg of 5 tetrahydrocannabinol (THC) or 5 mg to 500 mg of cannabidiol (CBD); and

a therapeutically effective amount of a sexual response enhancing component selected from the group consisting of sildenafil, tadalafil, and vardenafil.

2. The pharmaceutical composition of claim 1, wherein the one or more dosage forms comprise a tablet, capsule, or suppository.

10 3. An ingestible dosage form for enhancing sexual response and sensitivity in a human, comprising:

an ingestible cannabinoid component comprising at least one of 5 mg to 500 mg of tetrahydrocannabinol (THC) or 5 mg to 500 mg of cannabidiol (CBD); and

a tablet or capsule that contains a sexual response enhancing component selected from a 15 therapeutically effective amount of sildenafil, tadalafil, or vardenafil and/or at least 1 g, such as at least 2 g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot,

PI2021000684-

0 8 FEB 2021

Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and/or damiana.

4. The ingestible dosage form of claim 3, wherein the ingestible cannabinoid component is selected from the group consisting of tablet, capsule, oral drops, lozenges, lollipops, food preparations, such as brownics, cookies, or chocolates, chews, gum drops, soft candies, hard candies, and liquid shots.

5

5. A composition for enhancing sexual response and sensitivity in a human, comprising:

a topical cannabinoid dosage form comprising at least one 5 mg to 500 mg of tetrahydrocannabinol (THC) or 5 mg to about 500 mg of cannabidiol (CBD); and

a tablet or capsule that contains a sexual response enhancing component selected from a therapeutically effective amount of sildenafil, tadalafil, or vardenafil in and/or at least 1 g, such as at least 2 g, of an herbal supplement comprising one or more of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium
 gangeticum, garlic combined with vitamin C, and/or damiana.

6. The composition of claim 5, wherein the topical cannabinoid dosage form is selected from the group consisting of massage oils, lotions, gels, creams, lubricants, genital sprays, vaginal patch, vaginal suppository, and anal suppository.

7. A composition for enhancing sexual response and sensitivity in a human, comprising:

a vaporizable and inhalable cannabinoid dosage form configured to provide at least one of a dose of 5 mg to 500 mg of tetrahydrocannabinol (THC) or a dose of 5 mg to 500 mg of cannabidiol (CBD); and

a tablet, capsule, or topical dosage form that contains a sexual response enhancing component
selected from a therapeutically effective amount of sildenafil, tadalafil, or vardenafil in and/or
at least 1 g, such as at least 2 g, of an herbal supplement comprising one or more of Larginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny
goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium
gangeticum, garlic combined with vitamin C, and/or damiana.

10 8. The composition of claim 7, wherein the vaporizable and inhalable cannabinoid dosage form is formulated for vaporization and inhalation using a heat vaporizer or a nebulizer.

9. A composition for treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, comprising:

a cannabinoid configured to be administered by ingestion, inhalation, or topically, the cannabinoid comprising at least one of tetrahydrocannabinol (THC) or cannabidiol (CBD); and

a sexual response component configured to be administered by ingestion and including an effective amount of a sexual response component selected from the group consisting of sildenafil, tadalafil, vardenafil, herbal supplement, and combinations thereof.

10. The composition of claim 9, wherein the cannabinoid comprises 5-500 mg, or 7.5-450 mg, or 10-400 mg, or 15-350 mg, or 20-300 mg, or 25-250 mg of THC and/or 5-500 mg, or 7.5-450 mg, or 10-400 mg, or 15-350 mg, or 20-300 mg, or 25-250 mg of CBD.

11. The composition of claim 9 or 10 at least one of claims 19 to 22, wherein the
cannabinoid is configured to be administered as an infused edible, oral drop, liquid shot,
capsule, or tablet.

12. The composition of claim 9 or 10, wherein the cannabinoid is configured to be administered by inhalation of a heat vaporized cannabis extract.

13. The composition of claim 9 or 10, wherein the cannabinoid is administered topically as
an oil, lotion, gel, cream, lubricant, genital spray, vaginal patch, vaginal suppository, or anal suppository.

14. The composition of any one of claims 9 to 13, wherein the sexual response component is an herbal supplement selected from the group consisting of L-arginine, L-citrulline, yahimbe root, ginseng (*e.g.*, Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, damiana, and combinations thereof.

15

15. A composition for treating sexual dysfunction and/or enhancing sexual response and sensitivity in a human, comprising:

a tablet or capsule comprising at least one of tetrahydrocannabinol (THC) or cannabidiol (CBD); and

a tablet or capsule comprising an effective amount of a sexual response component selected from the group consisting of sildenafil, tadalafil, vardenafil, L-arginine, herbal supplement, and combinations thereof.

5

ABSTRACT

COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTION AND ENHANCING SEXUAL RESPONSE AND PLEASURE

Pharmaceutical preparations include at least one component that enhances sexual
response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus *Cannabis*,
including extracted compounds, synthetic forms, and derivatives thereof. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of *Cannabis*, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.

PIZUZ1000684-

39

ASSIGNMENT

WHEREAS, Assignor, ILYSM, LLC, a limited liability company organized and existing under the laws of the State of Utah, with a principal place of business at 6591 South Cottonwood Street, Murray, Utah 84107, is the assignee of record of the entire right, title and interest in and to the following patent applications and the inventions disclosed therein:

United States Patent Application No. 16/056,726, filed August 7, 2018 United States Patent Application No. 16/170,446, filed October 25, 2018 International Patent Application No. PCT/US2018/0597, filed November 17, 2018; and Canadian Patent Application No. 3,049,874, filed July 19, 2019.

WHEREAS, Assignor, ILYSM, LLC wishes to assign the entire right, title, and interest in and to the said patent applications and the inventions disclosed therein to ILYLT, LLC, a limited liability company organized and existing under the laws of Utah and having a principal place of business at 6591 South Cottonwood Street, Murray, Utah 84107.

WHEREAS, Assignee, ILYLT, LLC, desires to secure the entire right, title, and interest in and to said patent applications and the inventions disclosed therein.

NOW THEREFORE, in exchange for good and valuable consideration paid to Assignor by Assignee, the receipt and sufficiency of which is hereby acknowledged,

ASSIGNOR HEREBY ASSIGNS TO ASSIGNEE:

The entire right, title, and interest in and to said patent applications and the inventions disclosed therein, and in all divisions, continuations and continuations-in-part thereof, and in any reissues or extensions of Letters Patent or Patents granted thereon, and in all corresponding applications which may be filed in the United States and countries foreign to the United States, and in all patents issuing thereon in the United States and foreign countries, as well as the right to sue for past infringement and damages under any and all such patents.

The right to file foreign patent applications on said invention in its own name, wherever such right may be legally exercised, including the right to claim the benefits of the International convention for such applications.

Assignor hereby authorizes and requests the United States Commissioner of Patents and Trademarks and such Patent Office officials in foreign countries as are duly authorized by their patent laws to issue patents to issue any and all patents on said invention to the Assignee as the owner of the entire interest, for the sole use of Assignee, its successors, assigns, and legal representatives.

Assignor hereby agrees, without further consideration and without expense, to sign all lawful papers and to perform all other lawful acts which Assignee may request of Assignor to make this Assignment fully effective, including, by way of example but not of limitation, the following:

Prompt execution of all original, divisional, substitute, reissue and other United States and foreign patent applications on the invention, and all lawful documents requested by Assignee to further the prosecution of any of such patent applications.

Cooperation to the best of Assignor's ability in the execution of all lawful documents, the production of evidence, nullification, reissue, extension or infringement proceedings involving the invention.

DATED Jan. 22, 2021 ASSIGNOR ILYSM, LLC By: Dennis M. Jenn Manager and Member By: John M. Guynn Manager and Member ACCEPTED JAN. 22, 2021 ASSIGNEE ILYLT, LLC By: Dennis M. Jern Manager and Member By: 🖉 John M. Guynn Manager and Member

P12021000684-

2

INTERNATIONAL SEARCH REPOR	INT	ERNA	TION.	AL SEA	RCHF	REPORT
----------------------------	-----	------	-------	--------	------	--------

•

ĩ

International application No.	
PCT/US2018/059712	

	SSIFICATION OF SUBJECT MATTER 61K 31/352; A61K 31/05; A61K 36/185; A6	1P 15/00 (2018.01)				
1						
According to International Patent Classification (IPC) or to both national classification and IPC						
	cumentation searched (classification system followed by History document	r classification symbols)				
1	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched USPC - 424/725; 514/453; 514/454 (keyword delimited)					
1	ta base consulted during the international search (name of History document	of data base and, where practicable, search to	ems used)			
C. DOCUN	MENTS CONSIDERED TO BE RELEVANT	an a				
Category*	Citation of document, with indication, where app	ropriate, of the relevant passages	Relevant to claim No.			
x	US 2018/0161284 A1 (CAPRIO) 14 June 2018 (14.06	3.2018) entire document	1, 2, 11, 12, 14-16, 19-21, 31-36			
Y			3, 13, 17, 18			
Y	US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 28 document	5 September 2014 (25.09.2014) entire	3, 13, 17, 18			
P, X	US 10,064,905 B1 (ILYSM LLC) 04 September 2018	(04.09.2018) entire document	1-3, 11-21, 31-36			
]						
		······································				
Furthe	r documents are listed in the continuation of Box C.	See patent family annex.				
"A" docume	categories of cited documents: nt defining the general state of the art which is not considered particular relevance	"T" fater document published after the inter date and not in conflict with the applid the principle or theory underlying the	cation but cited to understand			
"E" earlier a filing da	pplication or patent but published on or after the international	"X" document of particular relevance; the considered novel or cannot be consid	claimed invention cannot be ered to involve an inventive			
cited to special r	establish the publication date of another citation or other reason (as specified)	"Y" document of particular relevance; the considered to involve an inventive	claimed invention cannot be step when the document is			
means	nt referring to an oral disclosure, use, exhibition or other nt published prior to the international filing date but later than	being obvious to a person skilled in th	e ari			
the prior	rity date claimed					
20 December	clual completion of the international search	Date of mailing of the international sear	сптерол			
	ailing address of the ISA/US	7.6 JAN 2019 Authorized officer				
Mail Stop PC	T, Attn: ISA/US, Commissioner for Patents	Biaine R. Copenhea	ver			
P.O. Box 1450, Alexandria, VA 22313-1450 Facsimile No. 571-273-8300 PCT Mebdesh: 571-272-1700 PCT OSP: 571-272-1774						

Form PCT/ISA/2:101 (second Isheet)) (January'2015)

INTERNATIONAL SEARCH REPORT	International application No.
	PCT/US2018/059712
Box No. II Observations where certain claims were found unsearchable (Continu	uation of item 2 of first sheet)
This international search report has not been established in respect of certain claims unde	er Article 17(2)(a) for the following reasons:
 Claims Nos.: because they relate to subject matter not required to be searched by this Author 	rity, nameły:
 Claims Nos.: because they relate to parts of the international application that do not comply extent that no meaningful international search can be carried out, specifically: 	with the prescribed requirements to such an
3. Claims Nos.: 4-10, 22-30 because they are dependent claims and are not drafted in accordance with the s	second and third sentences of Rule 6.4(a).
Box No. 111 Observations where unity of invention is lacking (Continuation of iter	m 3 of first sheet)
This International Searching Authority found multiple inventions in this international app	
 As all required additional search fees were timely paid by the applicant, this int claims. 	ernational search report covers all scarchable
 As all searchable claims could be searched without effort justifying additional additional fees. 	fees, this Authority did not invite payment of
3. As only some of the required additional search fees were timely paid by the appoint only those claims for which fees were paid, specifically claims Nos.:	olicant, this international search report covers
4. No required additional search fees were timely paid by the applicant. Cons restricted to the invention first mentioned in the claims; it is covered by claims	sequently, this international search report is 5 Nos.:
Remark on Protest The additional search fees were accompanied by the payment of a protest fee. The additional search fees were accompanied by the fee was not paid within the time limit specified in the becompanied by the fee was not paid within the time limit specified in the	applicant's protest but the applicable protest e invitation.
No protest accompanied the payment of additional s	Çalur 105.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2015)

-

i

	Verified		DOCKETED
_{By:} kplatt	_{On:} 18 Ja	n 2019	Atty JMG Fie# 15257.20B By DAnderson On 18 Jan 20
			Action Article 19 Amendments
1	PATENT COOPEI	KATION I KEAT	Response Due 12/110
From the INTERNATIONAL SEAR	CHING AUTHORITY		Submit IDR
To: JOHN M. GUYNN WORKMAN NYDEGGER 60 EAST SOUTH TEMPLE SUITE 1000 SALT LAKE CTIY, UT 84111		THE INTERNAT	PCT TION OF TRANSMITTAL OF TIONAL SEARCH REPORT AND TIONAL SEARCH REPORT AND
		SEARCHING AUT	HORITY, OR THE DECLARATION
		Date of mailing (doy'month year)	(PCT Rule 44.1) 6 JAN 2019
Applicant's or agent's file reference	j	logy month years	
15257-20B		FOR FURTHER AC	TION See paragraphs 1 and 4 below
International application No.		International filing date (day'month'year)	
PCT/US2018/059712		Loay monin years	07 November 2018
Applicant ILYSM, LLC			
Article 17(2)(a) to that effect a 3. With regard to any protest a the protest together with	ied that no international s and the written opinion of gainst payment of (an) add n the decision thereon has	carch report will be est the International Searchi ditional fee(s) under Rul- been transmitted to the	ablished and that the declaration under ing Authority are transmitted herewith. e 40.2, the applicant is notified that: International Bureau together with any
request to forward the te	exts of both the protest and	I the decision thereon to	
to the International Bureau. The	se comments will be mad copy of such comments	ie available to the publ	the International Searching Authority ic after international publication. The ces unless an international preliminary
Shortly after the expiration of 18 in International Bureau. If the application, or of the priority claim, international publication (Rules 90	months from the priority cant wishes to avoid or po- must reach the Internation bis.1 and 90bis.3).	ostpone publication, a n tal Bureau before the cor	al application will be published by the otice of withdrawal of the international npletion of the technical preparations for
examination must be filed if the app date (in some Offices even later); prescribed acts for entry into the r time limit of 30 months (or later) v	licant wishes to postpone to otherwise, the applican national phase before those will apply even if no deman	he entry into the national t must, within 20 mon te designated Offices. It id is filed within 19 mon	s, a demand for international preliminary phase until 30 months from the priority ths from the priority date, perform the respect of other designated Offices, the ths. For details about the applicable time <i>ipplicant's Guide</i> , National Chapters.
out by a different International Second	earching Authority that o	ffers this service (Rule	entary international search be carried 45bis.1). The procedure for requesting ational Phase, paragraphs 8.006-8.032.
Name and mailing address of the ISA/U	s	Authorized officer	
Mail Stop PCT, Altn: ISA/US Commissioner for Patents		Bla	ine R. Copenheaver
P.O. Box 1450, Alexandria, VA 22313-1450		PCT Helpo	est: 571-272-4300
Facsimile No. 571-273-8300		Telephone No. PCT OSP.	571-272-7774

Form PCT/ISA/220 (July 2017)

.

ī

•

P12021000684-

.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 15257-208	FOR FURTHER ACTION	as well	see Form PCT/ISA/220 as, where applicable, item 5 below.
International application No. PCT/US2018/059712	International filing date (day/me 07 November 2018	onth/year)	(Earliest) Priority Date (day/month/year) 07 August 2018
Applicant ILYSM, LLC			••••••••••••••••••••••••••••••••••••••
This international search report has be according to Article 18. A copy is bein	ten prepared by this International	Searching J	Authority and is transmitted to the applicant
This international search report consist	-		
	a copy of each prior art document	cited in this	report.
 Basis of the report Basis of the report With regard to the language, the language of the language of the language of the language. 	us international castch was carried	out on the h	netic of
	plication in the language in which		
a translation of the	international application into		which is the language of
	ned for the purposes of internation		
	report has been established takin to this Authority under Rule 91 (R		unt the rectification of an obvious mistake (a)).
	•		n the international application, see Box No. 1.
2. 🔀 Certain claims were fou	nd unsearchable (see Box No. 11).		
3. Unity of invention is lact	king (see Box No. 111).		
4. With regard to the title,			
the text is approved as sul	builted by the applicant		
	ied by this Authority to read as fol	lows:	
5. With regard to the abstract,			
the text is approved as su	• • •		
			s it appears in Box No. IV. The applicant may, eport, submit comments to this Authority.
6. With regard to the drawings,			
a. the figure of the drawings to b	e published with the abstract is Fig	gure No	un
as suggested by the	applicant.		
	Authority, because the applicant fa		-
	Authority, because this figure bette	r characterit	zes the invention.
b. none of the figures is to b	e published with the abstract.		
Form PCT/ISA/210 (first sheet) (January	2015)		

INTERNATIONAL SEARCH REPORT	International application No.
	PCT/US2018/059712
Box No. II Observations where certain claims were found unsearchable (Continu	untion of item 2 of first sheet)
This international search report has not been established in respect of certain claims unde	er Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Author	rity, namely:
 Claims Nos.: because they relate to parts of the international application that do not comply extent that no meaningful international search can be carried out, specifically: 	r with the prescribed requirements to such an
3. Claims Nos.: 4-10, 22-30 because they are dependent claims and are not drafted in accordance with the s	second and third sentences of Rule 6.4(a).
Box No. III Observations where unity of invention is lacking (Continuation of ite	m 3 of first sheet)
This International Searching Authority found multiple inventions in this international ap	plication, as follows:
1. As all required additional search fees were timely paid by the applicant, this int claims.	ternational search report covers all searchable
2. As all searchable claims could be searched without effort justifying additional additional fees.	fees, this Authority did not invite payment of
3. As only some of the required additional search fees were timely paid by the app only those claims for which fees were paid, specifically claims Nos.:	plicant, this international search report covers
4. No required additional search fees were timely paid by the applicant. Con- restricted to the invention first mentioned in the claims; it is covered by claims	
Remark on Protest The additional search fees were accompanied by the payment of a protest fee. The additional search fees were accompanied by the fee was not paid within the time limit specified in th No protest accompanied the payment of additional s	applicant's protest but the applicable protest ac invitation.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2015)

.

÷

CLASSIFICATION OF SUBJECT MATTER PC(8) - ASIK 31/352; ASIK 31/05; ASIK 36/165; ASIP 15/00 (2018.01) CFC - ASIK 31/352; ASIK 31/05; ASIK 36/165 (2018.08) According to International Pattern Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbol) See Search History document Documentation searched following the international search fame of data base and, where practicable, search terms used) See Search History document C. DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of documents, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 2014028708 BA1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) entire F, X US 10,064.905 B1 (ILVSM LLC) 04 September 2018 (04.09.2018) entire document F. Social exercises of clife documents Concent of the structure in the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority is experimented of the structure of the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority the priorities of the structure of the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority the priorities of the international filing date or priority the priorities of the priority chained on or filent the international filing date or priority the priority of the international filing		INTERNATIONAL SEARCH REPOR	ſ	International appl	ication No.
IPC(8) - A61K 31/352; A61K 31/05; A61K 36/185; A61P 15/00 (2018.01) CPC - A61K 31/352; A61K 31/05; A61K 36/185 (2018.08) According to International Patern Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Mainum documentation zearchet (classification system followed by classification symbols) See Search Hitkoy document Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched USC - 424/73; 514/453 (14/454 (Reyword delimited) Betconic data base consulted during the international search (name of data base and, where practicable, search terms und) Sea Search Hitsby document Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category* Citation of document, with indication, where appropriate, of the relevant passages 1, 2, 11, 12, 14-16, 19-21, 31-36 Y US 2016/012/264 A1 (CAPRIO) 14 June 2018 (14.08.2016) entire document 1, 3, 17, 18 Y US 2014/0227058 A1 (BIOTECH INSTITUTE LLC) 28 September 2014 (25.09.2014) entire 3, 13, 17, 18 Y US 10,084,905 B1 (ILVSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 *** Securent daming the pipelsetion or pathibited on or other in maximula documents arelisted in the continuation of Box C. **				PCT/US2010	3/059712
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) See Search History document Documentation searched during the international search (name of data base and, where practicable, search terms used) See Search History document C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 2016/0161284 A4 (CAPRIO) 14 June 2018 (14.06.2016) enline document V US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) enline document US 10,064.905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) enline document V US 10,064.905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) enline document C. DOCUMENTS CONSIDERED To Be Relevant to claim No. X US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) enline document V US 10,064.905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) enline document II.3, 11.21, 31.36 T V US 10,064.905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) enline document T Secial categories of clied documents: C. document which may throw doubs on epicity claim(3) or which is not considered T C. document which may throw doubs on epicity claim(3) or which is not considered T C. document which may throw doubs on enter the international T C. document metation all dicloares, exclubition or other T C. document network at the international filing date or priority is taken alone T C. document metation all dicloares, exclubition or other T C. document metation all dicloares, exclubition or other T T C. document and mailing address of the ISA/US Mal Biop PCT. Atr: ISA/US, Commissioner for Patonts PC Index133, 1340	IPC(8) - A	61K 31/352; A61K 31/05; A61K 36/185; A61)	
Minimum documentation searched (classification system followed by classification symbols) See Search History document Documentation searched (classification system followed by classification symbols) See Search History document Decumentation searched other than minimum documentation to the extent that such documents are included in the fields seorched USPC - 4247725; 514/453; 514/454 (keyword delimited) Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See Search History document C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages X US 2018/0191284 A1 (CAPRIO) 14 June 2018 (14:08:2018) enline document 11:3, 11; 11:1, 14:16, 19:21, 31:36 Y US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25:09:2014) enline 3, 13, 17, 18 P, X US 10,064;905 B1 (LLYSM LLC) 04 September 2018 (04:09:2018) enline document 1-3, 11:21, 31:36 *** Secial categories of cited documents: **** Secial categories of cited documents: ****** ** Special categories of cited documents: ************************************	According to	International Patent Classification (IPC) or to both n	ational classification a	nd IPC	
See Search History document Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched USPC - 424725; 514453; 514454 (teyword delimited) Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See Search Pistory document C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 2016/0161284 A1 (CAPRIO) 14 June 2018 (14.06 2016) entire document 1, 2, 11, 12, 14.16, 19.21, 31.36 Y US 2016/0161286 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) entire 3, 13, 17, 18 Y US 10,064,905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 P,X US 10,064,905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 *** Special categories of cited documents: *** ** Special categories of cited documents: *** *** Special categories of cited documents: *** *** Special categories of cited documents: *** *** Special categories of cited documents: **** *** Special c	B. FIELI	DS SEARCHED			
USPC - 424725; 514/453; 514/454 (keyword delimited) Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See Search History document C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 2016/018/284 A1 (CAPRIO) 14 June 2016 (14.06.2016) enline document 7 US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) enline document P,X US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) enline document P,X US 10,064.905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) enline document 1-3, 11-21, 31-36 Further documents are listed in the continuation of Box C. * Special categories of cited documents: * Special categories of cited documents: * Special categories of cited documents: * Cocument of particular relevance, the claimed investion cannot be considered to investion base on biolow as investion * Cocument of particular relevance, the claimed investion cannot be considered of investion cannot be consider	1		classification symbols)		
See Search History document C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 2018/0161284 A1 (CAPRIO) 14 June 2016 (14.06.2018) entire document 1, 2, 11, 12, 14-16, 19-21, 31-36 Y US 2018/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) entire 3, 13, 17, 18 Y US 10,064,905 B1 (JLYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 P, X US 10,064,905 B1 (JLYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 ** Special categories of cited documents: ************************************			tent that such documen	is are included in the	fields searched
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X US 2018/0161284 A1 (CAPRIO) 14 June 2018 (14.06.2018) enline document 1, 2, 11, 12, 14.16, 19-21, 31-36 Y US 2018/0161284 A1 (CAPRIO) 14 June 2018 (14.06.2018) enline document 3, 13, 17, 18 Y US 2018/0287/068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) entire 3, 13, 17, 18 Y US 10,064,905 B1 (LYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 P,X US 10,064,905 B1 (LYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 ** Special categories of cited documents: ** ** Special categories of cited documents: ** ** Tate document published on or after the international filing date or priority claim(s) or which is not considered to involve as inventive the principle or particular relevance. ** ** Cocument of particular relevance; the claimed invention cannot be considered to involve as inventive the principle or particular relevance; the claimed invention cannot be considered to involve as inventive the principle or particular relevance; the claimed invention cannot be considered to involve as inventive the principle or particular relevance; the claimed invention cannot be considered to involve as inventive the principle or particular relevance; the claimed invention cannot be consindered to involve as invention cannot be considered to i	1	-	f data base and, where j	practicable, search te	rms used)
X US 2018/0161284 A1 (CAPRIO) 14 June 2018 (14.06.2018) entire document 1, 2, 11, 12, 14.16, 19-21, 31-36 Y US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) entire 3, 13, 17, 18 Y US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) entire 3, 13, 17, 18 P, X US 10,064,905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2019 (2019) entities of the september 2018 (04.09.2018) entities document 1-3, 11-21, 31-36 Image: September 2019 (2019) entities of the september 2018 (04.09.2018) entities document 1-3, 11-21, 31-36 Image: September 2018 (2019) entities of the Istantional Search entities of the september 2018 (2019) entities of the september 2018 (2019) entities of the september 2018 (2019) entities entities of the september 2018 (2019) entities entities of the september 2019 Image: Sept 1450, Alaxember 2018 (201	C. DOCUN	MENTS CONSIDERED TO BE RELEVANT		·····	
Y US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.09.2014) entire 3, 13, 17, 18 Y US 10,064,905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 P,X US 10,064,905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: Septime to the septim to the septime to the septime to the septime to the septime to	Category*	Citation of document, with indication, where app	ropriate, of the relevan	t passages	Relevant to claim No.
Y US 2014/0287068 A1 (BIOTECH INSTITUTE LLC) 25 September 2014 (25.08.2014) entire document 3, 13, 17, 18 P, X US 10,064,905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: September 2018 (05.000 entire) entire	x	US 2018/0161284 A1 (CAPRIO) 14 June 2018 (14.06	.2018) entire documen	L	1, 2, 11, 12, 14-16, 19-21, 31-36
document Iter document 1-3, 11-21, 31-36 P, X US 10,064,905 B1 (ILYSM LLC) 04 September 2018 (04.09.2018) entire document 1-3, 11-21, 31-36 Image: Septial categories of cited documents: See patent family annex. 1-3, 11-21, 31-36 ** Special categories of cited documents: ** ** Special categories of cited documents: ** ** Special categories of cited documents: ** ** document defining the general state of the an which is not considered to be of particular relevance ** ** document of particular relevance ** ** document which may threw doubts on priority claim(\$) or which is relevance to cannot be considered to involve an inventive step when the document is relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more shifted in the antive step when the document is combined with one or more shifted in the antive step when the document is combined with one or more shifted in the antive step when the document is combined with one or more shifted in the antive step when the document is combined with one or more shifted in the antive step when the document is being dovisus to a person skilled in the antive step when the document is combination the priority date claimed *** document member of the same patent family Date of the stall completion of the international search 20 December 2018	v				3, 13, 17, 18
Further documents are listed in the continuation of Box C. See patent family annex. Secial categories of cited documents: Gocument defining the general state of the art which is not considered to be of particular relevance Gocument which may throw doubts on priority claim(s) or which is cited to stabilish the publication date of another citation of other gocument which may throw doubts on priority claim(s) or which is cited to stabilish the publication date of another citation of other means "" document published approximation "" document referring to an oral disclosure, use, exhibition or other means "" document published prior to the international filing date but later than "Pro document published prior to the international filing date but later than "Pro document published prior to the international filing date but later than "Pro document published prior to the international filing date but later than "Pro document published prior to the international filing date but later than "Pro Box 1450, Alaxmendria, VA 22313-1450 "Authorized officer "Pro Box 1450, Alaxmendria, VA 22313-1450 "Pro Box 1450, Alaxmendr	Y		September 2014 (25.0)9.2014) entire	3, 13, 17, 18
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent bul published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered to involve an inventive step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 20 December 2018 Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 		US 10,004,905 B1 (ILTSM LLC) 04 September 2016	(v4.09.2015) entire doc	υπε ηι	1-3, 11-21, 31-30
 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international ""A" document date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken after the international and the principle or theory underlying the invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken after the international search and the principle or the same patent family "O" document published prior to the international filing date but later than the priority date claimed "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 20 December 2018 Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 PCT Hepdest: 571-2724300 			See patent	family annex.	
20 December 2018 16 JAN 2019 Name and mailing address of the ISA/US Authorized officer Mail Stop PCT, Attn: ISA/US, Commissioner for Patents Biaine R. Copenheaver P.O. Box 1450, Alexandria, VA 22313-1450 PCT Hepdelt: 571-272-4300	"A" docume to be of "E" earlier a filing di "L" docume cited to special "O" docume means "P" docume	nt defining the general state of the art which is not considered particular relevance pplication or patent but published on or after the international at its the publication date of another citation or which is establish the publication date of another citation or other reason (as specified) nt referring to an oral disclosure, use, exhibition or other nt published prior to the international filing date but later than	date and not in c the principle or t "X" document of par considered nove step when the dc "Y" document of par considered to in combined with o being obvious to	onflict with the appli- heory underlying the ticular relevance; the l or cannot be consid- coument is taken alon- ticular relevance; the avolve an inventive ne or more other such a person skilled in the	cation but cited to understand invention claimed invention cannot be ered to involve an inventive claimed invention cannot be step when the document is document, such combination e art
Name and mailing address of the ISA/US Authorized officer Mail Stop PCT, Attn: ISA/US, Commissioner for Patents Bialne R. Copenheaver P.O. Box 1450, Alexandria, VA 22313-1450 PCT Hebdelt: 571-272-4300					rch report
Mail Stop PCT, Attn: iSA/US, Commissioner for Patents Biaine R. Copenheaver P.O. Box 1450, Alexandria, VA 22313-1450 PCT Heptent: \$71-272-4300	20 Decembe	r 2018	16 J	AN 2019	
Form PCT/ISA/210 (second sheet) (January 2015)	Mail Stop PC P.O. Box 145 Facsimile No	T, Ath: ISAUS, Commissioner for Patents 0, Alexandria, VA 22313-1450 2- 571-273-8300	E PCT Helpdest: 571-272-430		vər

Verified				DCKETED
By: kplatt On: 18	Jan 2019		Atty_JMGFile#_1 By DAnderson	On 18 Jan 2019
By: the date of th	Can Lo ro		Action Written Opi	
	PATENT COOPE	RATION TREA		
From the				
NTERNATIONAL SEARCHING AUT	HORITY)	DAT	
^{To:} JOHN M. GUYNN WORKMAN NYDEGGER 60 EAST SOUTH TEMPLE SUITE 1000 SALT LAKE CTIY, UT 84111		PCT WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43 <i>bis.</i> 1)		RITY
		Date of mailing (day/month/year)	16 JAN 2019	
Applicant's or agent's file reference		FOR FURTHER A	CTION	
15257-20B			See paragraph 2 below	
International application No.	International filing date		Priority date (day/month/year)	
PCT/US2018/059712 International Patent Classification (IPC	07 November 2018		07 August 2018	
Applicant ILYSM, LLC 1. This opinion contains indications in Basis of the	•	:ms:		
Box No. II Priority				
Box No. III Non-establis	hment of opinion with reg	ard to novelty, inventiv	e step and industrial applicability	
Box No. IV Lack of unit	y of invention			
Box No. V Reasoned sta citations and	tement under Rute 43bis. 1(explanations supporting s	a)(i) with regard to nove uch statement	ity, inventive step and industrial app	olicability;
Box No. VI Certain docu	ments cited			
Box No. VII Certain defe	cts in the international app	lication		
Box No. VIII Certain obse	rvations on the internation	al application		
2. FURTHER ACTION If a demand for international prel International Preliminary Examini other than this one to be the IPEA opinions of this International Sear If this opinion is, as provided abov a written reply together, where app PCT/ISA/220 or before the expirat For further options, see Form PCT	ng Authority ("IPEA") exc and the chosen IPEA has ching Authority will not be e, considered to be a writte ropriate, with amendments ion of 22 months from the	ept that this does not ap notified the Internation so considered. n opinion of the IPEA, s, before the expiration	ply where the applicant chooses an al Bureau under Rule 66.1 <i>bis</i> (b) th the applicant is invited to submit to of 3 months from the date of mailin	Authority hat written the IPEA
				J
Name and mailing address of the ISA/L Mail Stop PCT, Attn: ISA/US	S Date of completion of	this opinion	Authorized officer	
Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 Facsimile No. 571-273-8300	20 December 20'	18	Blaine R. Copenheaver PCT Hebdesk: 571-272-4300 PCT OSP: 571-272-7774	

٠

Form PCT/ISA/237 (cover sheet) (January 2015)

,

WRITTEN OPINION OF THE	International application No.
INTERNATIONAL SEARCHING AUTHORITY	PCT/US2018/059712
Box No. I Basis of this opinion	
1. With regard to the language, this opinion has been established on the basis of:	
the international application in the language in which it was filed.	
a translation of the international application into furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))	which is the language of a translation
2. This opinion has been established taking into account the rectification of an o this Authority under Rule 91 (Rule 43 <i>bis.</i> 1(a)).	bvious mistake authorized by or notified to
3. With regard to any nucleotide and/or amino acid sequence disclosed in the been established on the basis of a sequence listing:	e international application, this opinion has
a. forming part of the international application as filed:	
in the form of an Annex C/ST.25 text file.	
on paper or in the form of an image file.	
b. furnished together with the international application under PCT Rule search only in the form of an Annex C/ST.25 text file.	13ter.1(a) for the purposes of international
c. furnished subsequent to the international filing date for the purposes	of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).	
on paper or in the form of an image file (Rule 13ter. 1(b) and A	dministrative Instructions, Section 713).
4. In addition, in the case that more than one version or copy of a sequence listi statements that the information in the subsequent or additional copies is identified or does not go beyond the application as filed, as appropriate, were furn	cal to that forming part of the application as
5. Additional comments:	
1	

э

Form PCT/ISA/237 (Box No. I) (January 2015)

	WRITTEN OPINION OF THE	International application No.
	INTERNATIONAL SEARCHING AUTHORITY	PCT/US2018/059712
Box No.	III Non-establishment of opinion with regard to novelty, inventive step at	nd industrial applicability
	tions whether the claimed invention appears to be novel, to involve an inventive e have not been examined in respect of:	step (to be non obvious), or to be industrially
	the entire international application.	
	claims Nos. 4-10, 22-30	
becau		
	the said international application, or the said claims Nos subject matter which does not require an international search (specify):	relate to the following
Claim 4-10	the description, claims or drawings <i>(Indicate particular elements below)</i> or sai are so unclear that no meaningful opinion could be formed <i>(specify)</i> : 0 and 22-30 are multiple dependent claims not drafted in accordance with the sec	
	the claims, or said claims Nos. by the description that no meaningful opinion could be formed <i>(specify)</i> :	are so inadequately supported
\boxtimes	no international search report has been established for said claims Nos. $\frac{4-10.2}{10}$	22-30
	a meaningful opinion could not be formed without the sequence listing; the app	licant did not within the neecribed time limit
	a meaningful opinion could not be formed without the sequence rising, the app furnish a sequence listing in the form of an Annex C/ST.25 text file International Searching Authority in the form and manner acceptable to comply with the standard provided for in Annex C of the Administrative	e, and such listing was not available to the it; or the sequence listing furnished did not
	 furnish a sequence listing on paper or in the form of an image file compl C of the Administrative Instructions, and such listing was not available to form and manner acceptable to it; or the sequence listing furnished did Annex C of the Administrative Instructions. pay the required late furnishing fee for the furnishing of a sequence 	lying with the standard provided for in Annex o the International Searching Authority in the not comply with the standard provided for in
	Rule 13ter. 1(a) or (b).	
	See Supplemental Box for further details.	

Form PCT/ISA/237 (Box No. III) (January 2015)

	WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY		International application No.		
Box No. V F	INTERNATIONAL	SEARCHING	J AUTHORITY	PCT/US2018/059712	
ć	teasoned statement un itations and explanati			elty, inventive step and industrial aj	pplicability;
1. Statement					
Novelty	(N)	Claims	3, 13, 17, 18		YES
		Claims	1, 2, 11, 12, 14-16, 19-21,	, 31-36	NO
Inventiv	e step (IS)	Claims	None		YES
		Claims	1-3, 11-21, 31-36	· · · · · · · · · · · · · · · · · · ·	NO
Industri	al applicability (IA)	Claims	1-3, 11-21, 31-36		YES
		Claims	None		NO
Claims 1, 2, 11, 1. Regarding Claim treatment of erect or deliver (Para, [form): a cannabin cannabis, or extra comprises cannati sexual response of composition may sall thereof; and c Regarding Claim derivative of CBD and cannabidivari Regarding Claim of erectile dyslux composition are s extract thereof, is amount of a nativer and anafi, avair same properties, cannabinold comp composition are s expsulos; Paras, embodiments, the labit or capsule ally eff	 Caprio discloses a phile dysfunction) in a hum 0/23], administrationc old component comprise ct thereof, is administer sinoid tetrahydrocannab inhancing component s comprise a therapeutica annabisAED may con 2, Caprio discloses the i bbhol (CBN), tetrahydro (Para. (0025), comprise nic acid (CBDVA)). Caprio discloses an stion; Para. (0032). Adm upplied either separatel administered in an amo erectile dysfunction dru il, sildenafil, tadalafit; i.e such as enhancing sext conant comprising at laz upplied either separatel 0005]-(0008], cannabis cannabis extract comp Para. (0023), componen- tion may also be orally, ective amount of silden: 	harmaceutical - harmaceutical - han (Para, [00 components of ed of at least of ered in an amou hand (THC)) or elected from til ally effective an mprise varden pharmaceutics ccannabivarin - a one or more - ingestible dos inistration may by or mixed tog punt from abou ag (AED), or pi at sensitivity) ast one of 5 mg ty or mixed tog punt from abou ag (AED), or pi at sensitivity) ast one of 5 mg ty or mixed tog ty or mixed tog punt from abou ag (AED), or pi at sensitivity) ast one of 5 mg ty or mixed tog the composition at sensitivity ast one of 5 mg ty or mixed tog the composition at sensitivity at least at a sensitivity at least at a sensitivity at one of 5 mg ty or mixed tog the composition at a sensitivity at a	17], 'subject' includeshuma the composition are supplied one of 5 mg to 500 mg of tetra inf from about 5 mg to about 5 5 mg to 500 mg of cannabidk he group consisting of sildena mount of an anti-eractile dysfu afil, avanafil, sildenafil, tedalar al composition of claim 1, whe (THCV), cannabigerol (CBG), cannabinoid selected fromc tage form for enhancing sexur y also be orallycapsules; Pa jether in unit dosage form) and it 5 mg to about 50 mgcom amaceuticati y acceptable sa aition is the claimed compositi in a human (Para. [0017], 'su g to 500 mg of tetrahydrocann jether in unit dosage form; Pair reof, is administered in an am hold tetrahydrocannabinol (TH position are supplied either se al contains a sexual response r vardenafil in (Paras. [0006]-]	al dysfunction (Abstract, compositions fi in), comprising one or more dosage for either separately or mixed together in hydrocannabinol (THC) (Paras. 10005). 50 mgIn some embodiments, the casi- 10 (CBD); and a therapeutically effective fid, tadalafil, and vardenafil (Paras. 1000 inction drug (AED), or pharmaceutically fil). rein the cannabinoid component furthe dronabinol, nabilone, a derivative of TI annabidiotic acid (CBDA), cannabidiva al response (Abstract, compositions for rrs. (D023), administration component d sensitivity (Paras. 10005)-(0007), canno it there includeshuma), comprising: a labinol (THC) (Para. 10023), component ject' includeshuma), comprising: a labinol (THC) (Para. 10023), component in (D023), Administration may also be o yount from about 5 mg to about 50 mg (C)) or 5 mg to 500 mg of cannabidiol(parately or mixed together in unit dosa	ms configured unit dosaga -{0008}, nabis extract a amount of a b6}-{0007}, y acceptable ir comprises a HC, or a HC, or a the treatmen is of the nabis, or effective mprise tly exhibit the in ingestible ts of the orally In some

.

P12021000684-

International application No.

PCT/US2018/059712

Box No. VIII Certain observations on the international application

The following observations on the clairly of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 31 and 33 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because claims 31 and 33 are indefinite for the following reasons:

Regarding claims 31 and 33, the claims fail to provide sufficient antecedent basis for "the cannabis extract." For purposes of the Written Opinion proposed, claims 31 and 33 have been analyzed as "a cannabis extract" to provide sufficient antecedent basis for "the cannabis extract," as best interproted.

Form PCT/ISA/237 (Box No. VIII) (January 2015)

Supplemental Box

in case the space in any of the preceding boxes is not sufficient. Continuation of:

Regarding Claim 14, Caprio discloses a composition for enhancing sexual response and sensitivity (Abstract, compositions for the treatment of erectile dysfunction; Paras, [0005]-[0007], cannabls, or extract thereof, is administered in an amount from about 5 mg to about 50 mg, composition may comprise a therapeutically effective amount of an anti-erectile dysfunction drug (AED), or pharmaceutically acceptable salt thereof; and cannabis...AED may comprise varianafi, studenafi, tadalafi; it.e., this composition is the claimed composition; thus, the composition must inherently exhibit the same properties, such as enhancing sexual sensitivity) in a human (Para, [0017], "subject" includes...human), comprising: a topical cannabinoid dosage form (Para, [0023], components of the composition are supplied either separately; Para, [0032], administer the cannabis extract or cannabloid/arti-ED agent combination, or pharmaceutical compositions comprising same, locally to the area in need of treatment, such as the groin rejoin or penis. This method of administration may be achieved by, for example, and not by way of Emitation, local infusion, topical application) comprising at least one 5 mg to 500 mg of tetrahydrocannabind (THC) (Paras. [0005]-[0008], cannabis, or extract thereof, is administered in en amount from about 5 mg to about 50 mg, ... in some embodiments, the cannabis extract comprises cannabinoid are supplied either separately; Para. [0023], dominotents of the composition are supplied in a human (FHC) (Paras. [0003]-[0008], cannabis, or extract thereof, is administered in en amount from about 5 mg to about 50 mg, ... about 500 mg of tetrahydrocannabind (THC) (Paras. [0023], components of the composition are supplied either separately; Para. [0032], Administration may also be orally... capsules (Para. [0023], components of the composition are supplied either separately; Para. [0032], Administration may also be orally... capsules (Para. [0023], components of the composition are supplied either separately; Para. [0032

Regarding Claim 15, Capito discloses the composition of claim 14, wherein the topical cannabinoid dosage form (Para. [0032], administer the cannabis extract or cannabinoid/antil-ED egent combination, or pharmaceutical compositions comprising same, locally to the area in need of treatment, such as the groin rejoin or ponis. This method of administration may be achieved by, for example, and not by way of ilmitation, local infusion, topical application) is selected from the group consisting of massage cls, lotions, gets, creams (Para. [0022], gets, creams), lubricants, genital sprays, vaginal patch, vaginal suppository, and anal suppository.

Regarding Claim 16, Caprio discloses a composition for enhancing sexual response and sensitivity (Abstract, compositions for the treatment of erectile dysfunction; Pares. [0005]-[0007], cannabis, or extract thereof, is administered in an amount from about 5 mg to about 50 mg...composition may comprise a therapeutically effective amount of an anti-erectile dysfunction drug (AED), or pharmaceutically acceptable salt thereof; and cannabis...AED may comprise vardenafi, avanafi, sildenafi, tadalafi, i.e., this composition is the claimed composition; thus, the composition must inherently exhibit the same properties, such as enhancing sexual sensitivity) in a human (Pare. [0017], "subject" includes...human), comprising: a vaporizable and inhalable cannabinoid dosage form (Para. [0032], administer the cannabis extract or cannabin/ed anti-ED agent combination, or pharmaceutical composition somprising same... Administration may also be...vapors; Para. [0023], administration...components of the composition are supplied eithor separately or mixed together in unit dosage form; Please See Applicants Specification, PCT/US/2018/059712, Para. [0089], stating "vapor that carries the components of interest and can be inhated;" i.e., vapor dosage form is halable) configured to provide at least one of a dose of 5 mg to 500 mg of tetrahydrocannabinol (THC) (Paras. [0005]-[0008], cannabis, or extract thereof, is administration may also be crally... capsules) that contains exponents of the composition are supplied either separately or mixed together in unit dosage form; Please. (composite), and a tablet, capsule, or topical dosage form; Para. [0023], administration may also be or of a dose of 5 mg to 500 mg of cannabidiol (CBD); and a tablet, capsule, or topical dosage form; Para. [0023], administration may also be or ally... capsules) that contains a sexual response enhancing components elected from a therapeutically effective amount of an anti-erectie dysfunction drug (AED), or pharmaceutically acceptable salt thereof; and cannabis.

Regarding Claim 19, Caprio discloses a method of treating sexual dysfunction (Abstract, methods and compositions for the treatment of erectile dysfunction) and/or enhancing sexual response and sensitivity in a human (Para. [0017], "subject" includes...human), comprising: administering by ingestion (Pare. [0023], components of the composition are supplied either separately or mixed together in unit dosage form; Pare. [0032], Administration may also be orally...capsules), inhalation, or topicality a cannabioold comprising at least one of tetrahydrocannabinol (THC) or cannabidiol (CBD) (Pare. [0008], in some embodiments, the cannabis extract comprises cannabidiol (CBD). In some embodiments, the cannabis extract comprises cannabinoid tetrahydrocannabinol (THC)); and administering by ingestion (Pare. [0023], components of the composition are supplied either separately or mixed together in unit dosage form; Pare. [0032], Administration may also be orally...capsules) an effective amount of a sexual response component selected from the group consisting of sildenafit, tadalafi, vardenafit (Pares. [0006]-[0007], composition may comprise a therepeutically effective amount of an anti-erectile dysfunction drug (AED), or phermaceutically acceptable salit thereof; and cannabis...AED may comprise vardenafit, avanafit, sildenafit, tadalafil), herbal supplement, and combinations thereof.

Regarding Claim 20, Caprio discloses the method of daim 19, wherein the cannabinoid comprises 5-500 mg, or 7.5- 450 mg, or 10-400 mg, or 15-350 mg, or 20-300 mg, or 25-250 mg of THC (Paras, [0005]-[0008], cannabis, or extract thereof, is administered in an amount from about 5 mg to about 50 mg... cannabis extract comprises cannabinoid tetrahydrocannabinol (THC)).

Regarding Claim 21, Caprio discloses the method of claim 19, wherein the cannabinoid comprises 5-500 mg, or 7.5-450 mg, or 10-400 mg, or 15-350 mg, or 20-300 mg, or 25-250 mg of CBD (Paras. [0005]-[0008], cannabis, or extract thereof, is administered in an amount from about 5 mg to about 50 mg...cannabis extract comprises cannabidiol (CBD)).

Form PCT/ISA/237 (Supplemental Box) (January 2015)

International application No.

PCT/US2018/059712

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Regarding Claim 31 (as best interpreted), Caprio discloses a method of treating sexual dysfunction (Abstract, methods and compositions for the treatment of erectile dysfunction) and/or enhancing sexual response and sensitivity in a human (Para. [0017], "subject" includes... human), comprising: administering a cannabinold via tablet or capsule, a cannabis extract comprising at least one of tetrahydrocannabinol (THC) (Para. [0023], components of the composition are supplied either separately or mixed together in unit dosage form; Para. [0032], Administration may also be orally...capsules; Para. [0008], in some embodiments, the cannabis extract comprises cannabined (tetrahydrocannabinol (THC)) or cannabidel (CBD); and administering via tablet or capsule (Para. [0023], components of the composition are supplied either separately or mixed together in unit dosage form; Para. [0032], Administration may also be orally...capsules; Para. [0008], in some embodiments, the cannabis extract comprises cannabined tetrahydrocannabinol (THC)) or cannabidel (CBD); and administering via tablet or capsule (Para. [0023], components of the composition are supplied either separately or mixed together in unit dosage form; Para. [0032], Administration may also be orally...capsules; an effective amount of a sexual response component selected from the group consisting of sildenafii, tadalafii, vardenafii (Paras. [0006], ecotop3, composition may comprise a therapeuticaty effective amount of an anti-erectile dysfunction drug (AED), or pharmaceutically acceptable salt thereof, and cannabis...AED may comprise vardenafii, avanafi, sidenafii, tadalafii, Lagiafii, herbal supplement, and combinations thereof.

Regarding Claim 32, Capric discloses the method of claim 31, wherein the sexual response component (Pare. [0006], composition may comprise...an anti-erectile dysfunction drug (AED)), is selected from the group consisting of sidenafii, tadatifii, and vardenafii (Para. [0007], AED may comprise vardenafii, avanafii, sildenafii, tadatafii).

Regarding Claim 33 (as best interpreted), Caprio discloses a method of treating sexual dysfunction (Abstract, methods and compositions for the treatment of erectile dysfunction) and/or enhancing sexual response and sensitivity in a human (Para. [0017], "subject" includes... human), comprising: administering a cannabinoid by ingestion of a tablet, a capsule, an infused edible, or liquid shot, a cannabis extract comprising at least one of tetrahydrocannabinoi (THC) (Para. [0023], components of the composition are supplied either separately or mixed together in unit dosage form; Para. [0032], Administration may also be orally...capsules; Para. [0008], in some embodiments, the cannabis extract comprises cannabinoid tetrahydrocannabinol (THC) (or cannabidiol (CBD); and administering by ingestion (Para. [0023], components of the composition are supplied either separately or mixed together in unit dosage form; Para. [0032], Administration may also be orally...capsules) an effective amount of a pharmaceutical selected from the group consisting of sidenafit, tadafafi, and vardenafit (Paras. [0007], composition may comprise a therapeutical effective amount of an anti-erectile dysfunction drug (AED), or pharmaceutical selected from the group consisting of sidenafit, tadafafi, and vardenafit (paras. [0007], composition may comprise a therapeutical selected from the group consisting of sidenafit, tadafafit, and vardenafit acceptable sait thereof; and cannabis...AED may comprise vardenafit, avanafit, sidenafit, tadafafit).

Regarding Claim 34, Caprio discloses the method of claim 33, wherein the pharmaceutical comprises sildenafil (Pares. [0006]-[0007], composition may comprise a therapeutically effective amount of an anti-erectile dysfunction drug (AED)...AED may comprise vardenafil, avanafil, sildenafil).

Regarding Claim 35, Caprio discloses the method of claim 33, wherein the pharmaceutical comprises tadalafil (Paras. [0006]-[0007], composition may comprise a therapeutically effective amount of an anti-erectile dysfunction drug (AED)...AED may comprise vardenaß, avanaß, sildenaß, tadalaßi).

Regarding Claim 36, Caprio discloses the method of claim 33, wherein the pharmaceutical comprises varidenafil (Paras. [0006]-[0007], composition may comprise a therapeutically effective amount of an anti-erectile dysfunction drug (AED)...AED may comprise varidenafil).

Claims 3, 13, 17, and 18 lack an inventive step under PCT Article 33(3) as being obvious over Caprio in view of Biotech Institute LLC (hereinafter Biotech).

Regarding Claim 3, Caprio discloses the pharmacautical composition of claim 1, wherein at least a portion of the cannabinoid component is obtained from plant parts of one or more plants (Para, [0025], from the bud of a marijuana plant...extract may comprise one or more cannabinoid), but fails to explicitly disclose plants selected from Cannabis sativa, Cennabis indice, and hybrids thereof. Biotech is in the field of compositions for the use of cannabis (Abstract), including medically (Para, [0200]) and teaches plants selected from Cannabis sativa, Cannabis indice (Para, [0211), cannabinoid found in Cannabis sativa and Cannabis indica), and hybrids thereof. It would have been obvious to one of ordinary skill in the art at the time of the invention to modify Caprio with the teaching of Biotech to detail plants selected from Cannabis sativa, Cannabis indice. The motivation for doing so would have been to detail plants that contain cannabinoid (Biotech, Para, [0211]) and thereby use it to treat erectile dysfunction (Caprio, Paras, [0006]-[0008]).

Regarding Claim 13, Caprio discloses the ingestible dosage form of claim 11, wherein the ingestible cannabinoid component (Para. [0023], components of the composition are supplied either separately or mixed together in unit dosage form; Para. [0032], Administration may also be orally...capsules; Pare. [0008], cannabis extract comprises at least one cannabinoid, but fails to explicitly disclose component is selected from the group consisting of oral drops, locanges, kolfipops, food preparations, such as brownies, cookies, or chocolates, chews, gum drops, soft candles, hard candies, and liquid shots. Biotech is in the field of compositions for the use of cannabis (Abstract), including medically (Para. [0200]) and teaches component is selected from the group consisting of oral drops, locanges, kolfipops, food preparations, such as brownies, cookies, or chocolates, chews, gum drops, soft candles, hard candies, and liquid shots. Biotech is in the field of compositions for the use of cannabis (Abstract), including medically (Para. [0200]) and teaches component is selected from the group consisting of oral drops, locanges, kolfipops, food preparations, such as brownies, [0413], Cannabis edibles such as candy, brownies, and other foods are a popular method of consuming cannabis), cookies, or chocolates, chews, gum drops, soft candies, hard candies, and figuid shots. It would have been obvious to one of ordinary skill in the art at the time of the invention to modify Caprio with the teaching of Biotech to detail component is selected from the group consisting of food preparations, such as brownies. The molivation for doing so would have been to detail a popular method for consuming cannabis for medicinal purposes (Biotech, Para. [0813]) and thereby use it to treat erectile dysfunction (Caprio, Paras. [0006]-[0008]).

Form PCT/ISA/237 (Supplemental Box) (January 2015)

International application No.

PCT/US2018/059712

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Regarding Claim 17, Caprio discloses the composition of claim 16, wherein the vaporizable and inhalable cannabinoid dosage form (Para. [0032], administer the cannabis extract or cannabinoid/anti-ED agent combination...Administration may also be...vapors; Para. [0023], administration...components of the composition are supplied either separately or mixed logather in unit dosage form; Please See Applicants Specification, PCT/US/2018/059712, Para. [0089], stating "vapor that carries the components of interest and can be inheled;" i.e., vapor dosage form is inhalable), but faits to explicitly disclose dosage is formulated for vaporization and inhalation using a heat vaporizer. Biotech is In the field of compositions for the use of cannabis (Abstract), Including medically (Para. [0200]) and teaches dosage is formulated for vaporization and inhalation using a heat vaporizer (Paras. [0871]-[0872], Vaporization is the process of heating a substance to its boiling point to release vapor containing the active constituents in a gaseous state. This vapor can be inhaled for vaporization and inhalation using a heat vaporizer (Paras. [0871]-[0872], Vaporization is the process of heating a substance to its boiling point to release vapor containing the active constituents in a gaseous state. This vapor can be inhaled for vaporization and inhalation using a heat vaporizer (Paras. [0871]-[0872], Vaporization is the process of neating a substance to its boiling point to release vapor containing the active constituents in a gaseous state. This vapor can be inhaled for vaporization and inhalation using a heat vaporizer (Paras. [0871]-[0872], Vaporization and inhalation using a heat vaporizer (Paras. [0871]) and thereby use it to treat eractlie dusting of Biotech to detail dosage is formulated for vaporization and inhalation using a heat vaporizer. The motivation for doing so would have been to detail how to inhale active agents without harmful Irritants and carcinogens (Biotech, Para. [0871]) and thereby use it to treat eractlie dys

Regarding Claim 18, Caprio discloses the composition of claim 16, wherein the vaporizable and inhalable cannabled dosage form (Para, [0032], administer the cannable extract or cannable old anti-ED agent combination...Administration may also be...vapors; Para. [0023], administration...components of the composition are supplied eithor separately or mixed together in unit dosage form; Please See Applicants Specification, PCT/US/2018/059712, Para. [0089], stating "vapor that carries the components of interost and can be inhaled;" i.e., vapor dosage form is inhalable), but fails to explicitly disclose dosage is formulated for vaporization and inhalation using a nebulizer. Biotech is in the field of compositions for the use of cannable (Abstract), including medically (Para. [0200]) and toaches dosage is formulated for vaporization (Para. [0871], Vaporization is the process of heating a substance to its bolling point to release vapor containing the active constituents in a gaseous state. This vapor can be inhaled to deliver the active agents in the drug) and inhalation using a nebulizer (Para. [0811], extracts of the present invention are designed to produce products for human or animal consumption via inhalation (via...nebulization)). It would have been obvious to one of ordinary skil in the art at the time of the invention to modify Caprio with the teaching of Biotech to detail dosage is formulated for vaporization and inhalation using a nebulizer. The motivation for doing so would have been to detail how to inhale active agents (Biotech, Para. [0811]) and thereby use it to treat eractile dysfunction (Caprio, Paras. [0006]-[0008]).

Claims 1-3, 11-21, and 31-36 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.

Form PCT/ISA/237 (Supplemental Box) (January 2015)

Verified	DOCKETED		
_{Bv:} kplatt _{On:} 18 J	an 2019	Atty JMG File# 15257.20B By DAnderson On 18 Jan 2019	
		Action Article 19 Amendments	
PATENI COOPE	ERATION TREATY	Response Due 12/7/19 Submit IDR	
From the INTERNATIONAL SEARCHING AUTHORITY			
To: JOHN M. GUYNN WORKMAN NYDEGGER 60 EAST SOUTH TEMPLE SUITE 1000 SALT LAKE CTIY, UT 84111	NOTIFICATION O THE INTERNATIONAL THE WRITTEN OPINION SEARCHING AUTHORIT (PCT I	CT F TRANSMITTAL OF L SEARCH REPORT AND OF THE INTERNATIONAL Y, OR THE DECLARATION Rule 44.1) A N 2019	
Applicant's or agent's file reference 15257-20B	FOR FURTHER ACTION	See paragraphs 1 and 4 below	
International application No.	International filing date		
PCT/US2018/059712		vember 2018	
Applicant ILYSM, LLC		·····	
 Filing of amendments and statement under Article 1 The applicant is entitled, if he so wishes, to amend the When? The time limit for filing such amendments is m search report. How? Directly to the International Bureau of WIPO p 1211 Geneva 20, Switzerland, Facsimile No. For more detailed instructions, see PCT Applicant's 2. The applicant is hereby notified that no international Article 17(2)(a) to that effect and the written opinion o 3. With regard to any protest against payment of (an) a the protest together with the decision thereon h request to forward the texts of both the protest an no decision has been made yet on the protest; th 4. Reminders The applicant may submit comments on an informal basis to the International Bureau. These comments will be m International Bureau. Will send a copy of such comment examination report has been or is to be established. Shortly after the expiration of 18 months from the prioril International Bureau. If the applicant wishes to avoid or application, or of the priority claim, must reach the Internation internation apublication (Rules 90<i>bis.</i>] and 90<i>bis.</i>]. Within 19 months from the priority date, but only in respect examination must be filed if the applicant wishes to postpony date (in some Offices even later); oitherwise, the applicant may out by a different International Searching Authority that immits, Office by Office, see www.wipo.int/pcden/texts/time. 	claims of the international applica normally two months from the date of verferably through ePCT or on paper : +41 22 338 82 70 Guide, International Phase, parager search report will be established if the International Searching Auth dditional fee(s) under Rule 40.2, th as been transmitted to the Internation of the decision thereon to the designet e applicant will be notified as soon on the written opinion of the Internation and the decision thereon to the designet additional fee(s) under Rule 40.2, the additional fee(s) under Rule 40.2, the abeen transmitted to the Internation of the written opinion of the Internation on the written opinion of the Internation on the written opinion of the Internation of the the international applic postpone publication, a notice of onal Bureau before the completion of some designated Offices, a demic the entry into the national phase u unt must, within 20 months for ose designated Offices. In respect and is filed within 19 months. For Jimits.html and the <i>PCT Applicant</i> ay request that a supplementary offers this service (Rule 45bis.1)	of transmittal of the international to, 34 chemin des Colombettes aphs 9.004 – 9.011. I and that the declaration under ority are transmitted herewith. the applicant is notified that: lional Bureau together with any gnated Offices. In as a decision is made. rnational Searching Authorlty international publication. The ss an international preliminary ation will be published by the withdrawal of the international of the technical preparations for and for international preliminary ntil 30 months from the priority the priority date, perform the of other designated Offices, the details about the applicable time V's Guide, National Chapters. international search be carried by the procedure for requesting	
Name and mailing address of the ISA/US	Authorized officer		
Mail Stop PCT, Attn: ISAUS Commissioner for Palents		Copenheaver	
P.O. Box 1450, Alexandria, VA 22313-1450 Facsimile No. 671-273-8300	PCT Hepdosic \$71-27 Telephone No. pct osp. 571-272.77	12-4300 74	

Form PCT/ISA/220 (July 2017)

.

.

•

PATENT COOPERATION TREATY

РСТ

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 15257-208	FOR FURTHER ACTION as well	see Form PCT/ISA/220 as, where applicable, item 5 below.
International application No. PCT/US2018/059712	International filing date (day/month/year) 07 November 2018	(Earliest) Priority Date (day/month/year) 07 August 2018
Applicant ILYSM, LLC	L₂₀₀	
according to Article 18. A copy is bein This international search report consists	g transmitted to the International Bureau.	Authority and is transmitted to the applicant report.
	e international search was carried out on the b lication in the language in which it was filed.	asis of:
	nternational application into ed for the purposes of international search (Ri	which is the language of iles 12.3(a) and 23.1(b)).
	report has been established taking into account to account to the second of the second secon	ant the rectification of an obvious mistake a)).
c. With regard to any nucleo	tide and/or amino acid sequence disclosed in	the international application, see Box No. 1.
2. 🛛 Certain claims were foun	d unsearchable (see Box No. 11).	
3. Unity of invention is lack	ing (see Box No. 111).	
4. With regard to the title, the text is approved as sub	mitted by the configent	
	d by this Authority to read as follows:	
5. With regard to the abstract,	an liter of San Alexandra and	
	· · ·	it appears in Box No. IV. The applicant may, port, submit comments to this Authority.
6. With regard to the drawings,		
a. the figure of the drawings to be as suggested by the a	published with the abstract is Figure No	
	uthority, because the applicant failed to sugge	st a figure.
	uthority, because this figure better characteriz	es the invention.
b. i none of the figures is to be	published with the abstract.	
		······································

Form PCT/ISA/210 (first sheet) (January 2015)

.

P12021000684-

٠

INTERNATIONAL SEARCH REPORT	International application No.
	PCT/US2018/059712
Box No. II Observations where certain claims were found unsearchable (Contin	uation of item 2 of first sheet)
This international search report has not been established in respect of certain claims unde	er Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Author	rity, namely:
 Claims Nos.: because they relate to parts of the international application that do not comply extent that no meaningful international search can be carried out, specifically: 	r with the prescribed requirements to such an
3. Claims Nos.: 4-10, 22-30 because they are dependent claims and are not drafted in accordance with the s	second and third sentences of Rule 6.4(a).
Box No. III Observations where unity of invention is tacking (Continuation of ite	m 3 of first sheet)
This International Searching Authority found multiple inventions in this international ap	plication, as follows:
1. As all required additional search fees were timely paid by the applicant, this int claims.	emational search report covers all searchable
 As all searchable claims could be searched without effort justifying additional additional fees. 	fees, this Authority did not invite payment of
3. As only some of the required additional search fees were timely paid by the app only those claims for which fees were paid, specifically claims Nos.:	plicant, this international search report covers
4. No required additional search fees were timely paid by the applicant. Cons restricted to the invention first mentioned in the claims; it is covered by claims	
Remark on Protest In the additional search fees were accompanied by the payment of a protest fee. In the additional search fees were accompanied by the fee was not paid within the time limit specified in the No protest accompanied the payment of additional search fees were accompanied by the fee was not paid within the time limit specified in the No protest accompanied the payment of additional search fees were accompanied by the fee was not paid within the time limit specified in the No protest accompanied the payment of additional search fees were accompanied by the fee was not paid within the time limit specified in the No protest accompanied the payment of additional search fees were accompanied by the fee was not paid within the time limit specified in the No protest accompanied the payment of additional search fees were accompanied by the fee was not paid within the time limit specified in the fees were accompanied by the fees were	applicant's protest but the applicable protest e invitation.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2015)

•

.

٠

	(19) World Intellectual Property Organization International Bureau (43) International Publication Date		(10) International Publication Number WO 2020/032988 A1
(51)	A61K31/352 (2006.01) A61K36/185 (2006.0)	blished; with international search report (Art. 21(3))
(21)		597 12	
(22)	÷	2018)	
(25)	Filing Language: E	nglish	
(26)	Publication Language: E	nglish	
(30)	Priority Data: 16/056,726 07 August 2018 (07.08.2018) 16/170,446 25 October 2018 (25.10.2018)	US US	
(71)	Applicant: ILYSM, LLC [US/US]; 6591 South C wood Street. Murray. Utah 84107 (US)	otton~	
(72)	Inventor: JENN, Dennis; 1878 Portabello Road, Jordan, Utah 84095 (US).	South	
(74)			
(81)	kind g national protection available): AE. AG. AL AO, AT. AU. AZ, BA. BB, BG, BH, BN, BR. BW, B' CA, CH, CL. CN, CO, CR, CU, CZ, DE, DJ, DK, DN DZ, EC, FE. EG, ES, FI, GB, GD, GE, GH, GM, GT HR, HU, ID, IL, IN, IR. IS, JO, JP, KE, KG, KH, KI KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM	, AM, Y, BZ, I, DO, T, HN, V, KP, Y, ME, D, NZ, Y, SA, I, TN,	
. ,	kind g regional protection available): ARIPO (BW GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, S UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, R TM), European (AL, AT, BE, BG, CH, CY, CZ, DE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK	, GH, Z. TZ, J. TJ, , DK, J. LV, , SM,	
(54) RESI (57) poun regio blood <i>Canv</i> the n The	PONSE AND PLEASURE Abstract: Pharmaceutical preparations include at lease id that enhances sexual sensitivity and pleasure. The c on. Examples include compounds that dilate blood vess d. The component that enhances sexual sensitivity and <i>nabis</i> , including extracted compounds, synthetic form main psychoactive constituent of <i>Cannabis</i> , and cannab	t one compo omponent th els, such as pleasure incl s, and deriva idiol (CBD),	nent that enhances sexual response and at least one other com- at enhances sexual response enhances blood flow to the genital compounds that increase the amount of nitric oxide (NO) in the udes one or more cannabinoid compounds from the plant genus tives thereof. Examples include tetrahydrocannabinol (THC), which is less or non-psychoactive and modulates THC activity.
	(21) (22) (25) (26) (30) (71) (72) (74) (81) (81) (84) (84) (84) (54) RES (57) pour regio blood Canu the n	 (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 February 2020 (13.02.2020) (51) International Patent Classification: A61K 31/352 (2006.01) A61K 36/185 (2006.01) A61K 31/05 (2006.01) A61K 31/05 (2006.01) A61F 15/00 (2006.01) (21) International Application Number: PCT/US20 18/0 (22) International Filing Date: 07 November 2018 (07. 11 (25) Filing Language: E (26) Publication Language: 16/056,726 07 August 2018 (07.08.2018) 16/170,446 25 October 2018 (25. 10.2018) 16/170,446 25 October 2018 (25. 10.2018) (71) Applicant: ILYSM, LLC [US/US]: 6591 South C wood Street. Murray. Utah 84107 (US) (72) Inventor: JENN, Dennis; 1878 Portabello Road, Jordan, Utah 84095 (US). (74) Agent: GUYNN, John M.; Workman Nydegger, 60 SouthTemple, Suite 1000, SaltLake Ctiy, Utah 841 11 (81) Designated States (unless otherwise indicated, for kind g national protection available): AE, AG, AL, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GJ HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NC OM, PA, PE, PG, PH, PL, PT, OA, RO, RS, RU, RW SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZV (84) Designated States (unless otherwise indicated, for kind g regional protection available): ARIPO (BW GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SV UC MA 24, ER, LS, MW, MZ, NA, RW, SD, SL, ST, SV UC MA 24, ER, LS, MW, MZ, NA, RW, SD, SL, ST, SV UC MA 24, ER, LS, MW, MZ, NA, RW, SD, SL, ST, SV UC MA 24, ER, LS, MW, MZ, NA, RW, SD, SL, ST, SV UC MA 24, ER, LS, MW, MZ, NA, RW, SD, SL, ST, SV UC MA 24, ER, LS, MW, MZ, NA, RW, SD, SL, ST, SV UC MA 24, ER, LS, MW, MZ, NA, RW, SD, SL, ST, SV UC MA 24, ER, LS, MW, MZ, NA, RW, SD, SL, ST, SV UC MA 24, ER, LS, MW, MZ, NA, RW,	Organization International Bureau (43) International Publication Date 13 February 2020 (13.02.2020) WIPOIPC (51) International Patent Classification: A61K 31/352 (2006.01) A61K 36/185 (2006.01) A61K 31/352 (2006.01) Publication States (2006.01) A61K 31/352 (2006.01) (21) International Application Number: PCT/US20 18/059712 Publication Language: 07 November 2018 (07. 11 2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16/056,726 07 August 2018 (07.08.2018) US 16/170,446 (30) Priority Data: 16/056,726 07 August 2018 (25.10.2018) US (71) Applicant: ILYSM, LLC [US/US]: 6591 South Cotton- wood Street, Murray, Utah 84107 (US) VI (72) Inventor: JENN, Dennis; 1878 Portabello Road, South Jordan, Utah 84095 (US). (24) Agent: GUVNN, John M.; Workman Nydegger, 60 East SouthTemple, Suite 1000, SaltLake Ctiy, Utah 841 11 (US). (81) Designated States (unless otherwise indicated, for every kind d national protection available): A. A. A. A. A. A.O. AT. AU. AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, C. A. CH, CL. CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, HL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, N, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, ZUA, UG, US, UZ, VC, VN, ZA, ZM, ZW. <td< th=""></td<>

INVOIS CUKAI DIPERMUDAHKAN PERBADANAN HARTA INTELEK MALAYSIA

Unit 1-7 Aras Bawah Tower B Menara UOA Bangsar No 5 Jalan Bangsar Utama 1, 59000, Kuala Lumpur, Malaysia. Tel: 603-2299 8400 Faks: 603-2299 8989 GST NO: 000869019648



Diterima Daripada Butiran Resit Rasmi				
TAI FOONG LAM	Nombor Resit	:	RST/IP-004404-2021	
C/O GAN PARTNERSHIP, D-32-02, MENARA SUEZCAP 1, KL GATEWAY, 2 JALAN KERINCHI, GERBANG KERINCHI LESTARI	Tarikh	:	08/02/2021 13:41:53	
Wilayah Persekutuan 59200 Kuala Lumpur (MY)	Jumlah	:	470.00	

Rujukan		Butiran Bayaran				
Pusat Bayaran	:	IBU PEJABAT-	Cara Bayaran	No Doc	Tarikh Doc	Amaun (RM)
No. Invois	:	2082964	CEK TEMPATAN	MBB166976	08/02/2021	470.00
Catatan	:		MBB			

Keterangan	No pendaftaran	Kuantiti	Kos Per Unit	GST	Jumlah
PM2A(a)	PI2021000684	1.00	290.00	0.00	290.00
PM2A(b)	PI2021000684	1.00	100.00	0.00	100.00
PM22	PI2021000684	1.00	80.00	0.00	80.00

Cetakan Berkomputer Tidak Perlu Tandatangan

*Resit ini akan dianggap batal sekiranya cek tidak dapat ditunaikan. Pelepasan di bawah Seksyen 56(3)(b) Akta Cukai Barangan dan Perkhidmatan 2014

GST NO: 000869019648

MUHAMMAD FIRDAUS BIN NONG CHIK SALINAN PELANGGAN

INVOIS	CUKAI	DIPERMUD	AHKAN
--------	--------------	----------	-------



PERBADANAN HARTA INTELEK MALAYSIA Unit 1-7 Aras Bawah Tower B Menara UOA Bangsar No 5 Jalan Bangsar Utama 1, 59000, Kuala Lumpur, Malaysia. Tel: 603-2299 8400 Faks: 603-2299 8989



Diterima Daripada	Butiran Resit Rasmi		
TAI FOONG LAM	Nombor Resit	:	RST/IP-004404-2021
C/O GAN PARTNERSHIP, D-32-02, MENARA SUEZCAP 1, KL GATEWAY, 2 JALAN KERINCHI, GERBANG KERINCHI LESTARI	Tarikh	:	08/02/2021 13:41:53
Wilayah Persekutuan 59200 Kuala Lumpur (MY)	Jumlah	:	470.00

Rujukan		Butiran Bayaran	Butiran Bayaran			
Pusat Bayaran	:	IBU PEJABAT-	Cara Bayaran	No Doc	Tarikh Doc	Amaun (RM)
No. Invois	:	2082964	CEK TEMPATAN	MBB166976	08/02/2021	470.00
Catatan	:		MBB			

Keterangan	No pendaftaran	Kuantiti	Kos Per Unit	GST	Jumlah
PM2A(a)	PI2021000684	1.00	290.00	0.00	290.00
PM2A(b)	PI2021000684	1.00	100.00	0.00	100.00
PM22	PI2021000684	1.00	80.00	0.00	80.00

Cetakan Berkomputer

Tidak Perlu Tandatangan *Resit ini akan dianggap batal sekiranya cek tidak dapat ditunaikan.

Pelepasan di bawah Seksyen 56(3)(b) Akta Cukai Barangan dan Perkhidmatan 2014